Pressure BioSciences (PBIO) 10-K 7 Jun 24 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2023	Jun. 04, 2024
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-38185
Entity Registrant Name	PRESSURE BIOSCIENCES, INC.
Entity Central Index Key	0000830656
Entity Tax Identification Number	04-2652826
Entity Incorporation, State or Country Code	MA
Entity Address, Address Line One	480 Neponset St.
Entity Address, City or Town	Canton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02021
City Area Code	(508)
Local Phone Number	230-1828
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float	$ 8,002,541
Entity Common Stock, Shares Outstanding		34,710,509
ICFR Auditor Attestation Flag	false
Auditor Firm ID	206
Auditor Name	MaloneBailey, LLP
Auditor Location	Houston, Texas

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 81,279	$ 3,865
Accounts receivable	151,234	295,374
Inventories, net of $1,021,812 and $982,973 reserve, respectively	304,909	686,383
Prepaid expenses and other current assets	222,633	257,527
Total current assets	760,055	1,243,149
Investment in equity securities	61,876	63,638
Property and equipment, net	84,930	103,351
Right of use asset leases	142,815	282,095
Intangible assets, net		317,308
TOTAL ASSETS	1,049,676	2,009,541
CURRENT LIABILITIES
Accounts payable	1,320,432	637,238
Accrued employee compensation	191,578	167,247
Accrued professional fees and other	2,860,509	2,497,762
Accrued interest and dividends payable	5,306,353	10,803,983
Deferred revenue	233,850	58,242
Convertible debt, net of unamortized debt discounts of $645,471 and $455,517, respectively	20,683,841	17,823,669
Other debt, net of unamortized discounts of $0 and $0, respectively	1,264,162	1,638,969
Right of use operating lease liability	66,895	142,171
Series BB convertible preferred stock liability	1,000,000
Total current liabilities	33,576,120	34,404,166
LONG TERM LIABILITIES
Long term debt	161,864	150,000
Right of use operating lease liability long term	60,961	139,924
Deferred revenue	4,560	1,822
TOTAL LIABILITIES	33,803,505	34,695,912
COMMITMENTS AND CONTINGENCIES (Notes 8)
STOCKHOLDERS’ DEFICIT
Series D, G, H, H2, J, K, AA, BB and CC Convertible Preferred Stock, $.01 par value (Note 10)	102	1,098
Common stock, $.01 par value; 100,000,000 shares authorized; 35,367,663 and 13,682,910 shares issued and outstanding on December 31, 2023 and December 31, 2022, respectively	353,677	136,829
Warrants to acquire common stock	35,684,321	31,995,762
Additional paid-in capital	100,236,710	69,006,145
Accumulated deficit	(169,028,639)	(133,826,205)
TOTAL STOCKHOLDERS’ DEFICIT	(32,753,829)	(32,686,371)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	1,049,676	2,009,541
Related Party [Member]
CURRENT LIABILITIES
Related party, net of unamortized debt discount of $0 and $7,915, respectively	$ 648,500	$ 634,885

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Inventory valuation reserves	$ 1,021,812	$ 982,973
Debt instrument, unamortized discount	645,471	455,517
Other debt, unamortized discounts net	$ 0	$ 0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares, issued	35,367,663	13,682,910
Common stock, shares, outstanding	35,367,663	13,682,910
Series D, G, H, H2, J, K, AA, BB and CC Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Convertible Debt [Member]
Debt instrument, unamortized discount	$ 645,471	$ 455,517
Related Party [Member]
Debt instrument, unamortized discount	$ 0	$ 7,915

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 1,977,763	$ 1,729,343
Costs and expenses:
Cost of products and services	1,178,201	2,014,004
Research and development	1,367,154	969,532
Selling and marketing	730,714	401,444
General and administrative	8,205,052	3,242,652
Total operating costs	11,481,121	6,627,632
Operating loss	(9,503,358)	(4,898,289)
Other (expense) income:
Interest expense, net	(15,581,440)	(10,438,565)
Unrealized (loss) gain on investment in equity securities	(1,762)	3,662
Loss on extinguishment of liabilities	(3,970,983)	(751,335)
Other expense	(256,755)	7,849
Total other expense	(19,810,940)	(11,178,389)
Net loss	(29,314,298)	(16,076,678)
Deemed dividends on extension of warrants	(3,626,950)
Preferred stock dividends	(2,261,186)	(1,727,275)
Net loss attributable to common shareholders	$ (35,202,434)	$ (17,803,953)
Basic net loss per share attributable to common shareholders	$ (1.51)	$ (1.61)
Diluted net loss per share attributable to common shareholders	$ (1.51)	$ (1.61)
Weighted average common shares outstanding used in the basic net loss per share calculation	23,336,620	11,058,356
Weighted average common shares outstanding used in the diluted net loss per share calculation	23,336,620	11,058,356
Products Services Other [Member]
Revenue:
Total revenue	$ 1,977,763	$ 1,729,343

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Warrant [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 1,099	$ 91,206	$ 31,715,154	$ 64,261,048	$ (118,277,468)	$ (22,208,961)
Beginning balance, shares at Dec. 31, 2021	109,878	9,120,526
Early adoption of ASU 2020-06				(2,728,243)	2,255,216	(473,027)
Stock-based compensation				215,098		215,098
Stock option exercise		$ 253		17,190		$ 17,443
Stock option exercise, shares		25,279				25,279
Series AA Preferred Stock dividend					(1,727,275)	$ (1,727,275)
Issuance of common stock for services		$ 2,555		389,620		$ 392,175
Issuance of common stock for services, shares		255,500				255,500
Warrants issued for debt extension			132,537			$ 132,537
Common stock issued for debt extension		$ 14,238		2,184,623		$ 2,198,861
Common stock issued for debt extension, shares		1,423,800	277,500			10,000
Conversion of debt and interest for common stock		$ 1,819		465,273		$ 467,092
Conversion of debt and interest for common stock, shares		181,918				181,918
Conversion of preferred stock for common stock	$ (1)	$ 44		(43)
Conversion of preferred stock for common stock, shares	(4)	4,400
Issuance of common stock for dividends paid-in-kind		$ 2,361		383,939		386,300
Issuance of common stock for dividends paid-in-kind, shares		236,221
Issuance of common stock for interest paid-in-kind		$ 17,663		2,925,476		2,943,139
Issuance of common stock for interest paid-in-kind, shares		1,766,266
Stock issued with debt		$ 6,590		867,264		873,854
Stock issued with debt, shares		659,000
Sale of Common Stock		$ 100		24,900		25,000
Sale of common stock for cash, shares		10,000
Warrants issued for services			54,495			54,495
Warrants issued with debt			93,576			93,576
Net loss					(16,076,678)	(16,076,678)
Issuance of preferred stock for services
Preferred stock issued with debt
Ending balance, value at Dec. 31, 2022	$ 1,098	$ 136,829	31,995,762	69,006,145	(133,826,205)	(32,686,371)
Ending balance, shares at Dec. 31, 2022	109,874	13,682,910
Stock-based compensation				2,636,443		2,636,443
Stock option exercise		$ 1,176		79,935		$ 81,111
Stock option exercise, shares		117,552				117,552
Series AA Preferred Stock dividend					(1,726,935)	$ (1,726,935)
Issuance of common stock for services		$ 21,500		1,999,435		2,020,935
Issuance of common stock for services, shares		2,150,000
Common stock issued for debt extension		$ 25,523		2,003,225		$ 2,028,748
Common stock issued for debt extension, shares		2,552,300	100,000			60,000
Conversion of debt and interest for common stock		$ 2,036		506,997		$ 509,033
Conversion of debt and interest for common stock, shares		203,613				203,613
Conversion of preferred stock for common stock	$ (1,012)	$ 29,920		(28,908)
Conversion of preferred stock for common stock, shares	(101,399)	2,991,940
Issuance of common stock for dividends paid-in-kind		$ 7,296		379,640		386,936
Issuance of common stock for dividends paid-in-kind, shares		729,571
Issuance of common stock for interest paid-in-kind		$ 118,781		8,107,405		8,226,186
Issuance of common stock for interest paid-in-kind, shares		11,878,135
Stock issued with debt		$ 16,256		774,719		790,975
Stock issued with debt, shares		1,625,642
Sale of Common Stock		$ 600		149,400		150,000
Net loss					(29,314,298)	(29,314,298)
Series CC Preferred Stock dividend					(534,251)	(534,251)
Series AA Preferred Stock Warrant Extension			3,626,950		(3,626,950)
Issuance of common stock warrants for services			61,609			61,609
Conversion of debt and interest for preferred stock	$ 4			10,017,208		10,017,212
Conversion of debt and interest for preferred stock, shares	401
Conversion of common stock to preferred stock	$ 1	$ (6,240)		6,239
Conversion of common stock to preferred stock, shares	62	(624,000)
Sale of common stock, shares		60,000
Issuance of preferred stock for services	$ 2			1,360,865		1,360,867
Issuance of preferred stock for services, shares	233
Preferred stock for debt extension	$ 8			2,674,522		2,674,530
Preferred stock for debt extension, shares	822
Preferred stock issued with debt	$ 1			563,440		563,441
Preferred stock issued with debt, shares	128
Ending balance, value at Dec. 31, 2023	$ 102	$ 353,677	$ 35,684,321	$ 100,236,710	$ (169,028,639)	$ (32,753,829)
Ending balance, shares at Dec. 31, 2023	10,121	35,367,663

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (29,314,298)	$ (16,076,678)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on loan forgiveness	(1,129,679)	(10,000)
Non-cash lease expense	139,280	113,470
Common stock and warrants issued for interest	8,226,186	2,943,139
Preferred stock issued for interest	602,616
Preferred stock issued for services	1,360,867
Depreciation and amortization	112,454	119,788
Accretion of interest and amortization of debt discount	2,507,055	1,777,863
Common stock and warrants issued for debt extension	2,028,748	2,331,398
Preferred stock issued for debt extension	3,071,914
Allowance for inventory reserve	121,891	641,815
Stock-based compensation expense	2,636,443	215,098
(Gain) loss on investment in equity securities	1,762	(3,662)
Common stock and warrants issued for services	2,082,544	446,670
Impairment on intangible assets	230,770
Changes in operating assets and liabilities:
Accounts receivable	144,140	(140,628)
Inventories	259,583	(180,644)
Prepaid expenses and other assets	34,894	165,090
Accounts payable	683,194	109,314
Accrued employee compensation	24,331	49,567
Operating lease liability	(154,239)	(113,470)
Deferred revenue and other accrued expenses	3,143,534	3,133,829
Net cash used in operating activities	(3,186,010)	(4,478,041)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property plant and equipment	(7,495)	(20,755)
Net cash used in investing activities	(7,495)	(20,755)
CASH FLOWS FROM FINANCING ACTIVITIES:
Sale of common stock	150,000	25,000
Proceeds from stock option exercises	81,111	17,443
Net proceeds from convertible debt	5,456,960	4,907,222
Net proceeds from non-convertible debt - third party	2,614,761	2,710,000
Net proceeds from related party	181,700	866,350
Payments on convertible debt	(2,742,409)	(1,522,494)
Payments on debt - related party	(185,000)	(315,300)
Payments on non-convertible debt	(2,286,204)	(2,317,871)
Net cash provided by financing activities	3,270,919	4,370,350
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	77,414	(128,446)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	3,865	132,311
CASH AND CASH EQUIVALENTS AT END OF PERIOD	81,279	3,865
SUPPLEMENTAL INFORMATION
Interest paid in cash	1,475,864	1,378,647
NON CASH TRANSACTIONS:
ASU 2020-06 adoption		473,027
Common stock issued with debt	790,975	873,854
Conversion of preferred stock for common stock	29,920	44
Conversion of common stock for preferred stock	6,240
Preferred stock issued with debt	563,441
Preferred Shares Liability	1,000,000
Discount from warrants issued with debt		93,576
Common stock issued in lieu of cash for dividend	386,936	386,300
Conversion of nonconvertible debt to convertible	691,500
Preferred stock dividends	2,261,186	1,727,275
Conversion of debt, interest, preferred stock dividend for preferred stock	10,017,212
Conversion of debt and interest into common stock	509,033	467,092
Extension of warrants for Series AA preferred stock	$ 3,626,950

Business Overview

Business Overview	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview	(1) Business Overview Pressure BioSciences, Inc. (OTCQB: PBIO The Company was founded on the belief that its PCT platform had the potential to significantly increase the quality of sample preparation in both research and clinical settings. This premise has been well proven and PBI has been successful in installing its PCT platform in the laboratories of key opinion leaders worldwide. Although developed subsequently, the Company now assesses that the commercial potential for its UST platform across diverse multi-billion-dollar markets far exceeds the potential of the PCT platform. Consequently, in January 2022, PBI made the critical strategy decision to immediately shift its primary business focus from PCT to its innovative UST Platform.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	(2) Going Concern We have experienced negative cash flows from operations since our inception. As of December 31, 2023, we did not have adequate working capital resources to satisfy our current liabilities and as a result we have substantial doubt about our ability to continue as a going concern. We have been successful in raising debt and equity capital in the past and as described in Notes 9 and 10. In addition, we raised debt and equity capital after December 31, 2023 as described in Note 11. We have financing efforts in place to continue to raise cash through debt and equity offerings. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. These financial statements do not include any adjustments that might result from this uncertainty. The conditions described above could adversely affect our ability to obtain additional financing on favorable terms, if at all, and may cause investors to have reservations about our long-term prospects and may adversely affect our relationships with customers. If we cannot successfully continue as a going concern, our stockholders may lose their entire investment.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(3) Summary of Significant Accounting Policies i. Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation. ii. Use of Estimates To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used. iii Recent Accounting Pronouncement In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires measurement and recognition of expected credit losses for financial assets held. We adopted this new accounting guidance effective January 1, 2023. The adoption did not have a material impact on our consolidated financial statements and disclosures and did not significantly impact the Company’s accounting policies or estimation methods related to the allowance for doubtful accounts. The Company does not have any reserve for doubtful accounts due to its customers being distributors, universities, research organizations and government agencies. In the past several years, all its customers have paid in full without any need for a write-down. In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $ 2,728,243 2,255,216 473,027 iv. Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. Most of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold, which were nominal in 2023 and 2022. We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Revenue from government grants is recorded when expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. [REFER TO 10K TABLES WORK BOOK – REV DETAIL TAB] Schedule of Disaggregation of Revenue In thousands of US dollars ($) Year Ended December 31, Primary geographical markets 2023 2022 North America 1,366 1,191 Europe 136 144 Asia 476 394 1,978 1,729 In thousands of US dollars ($) Year Ended December 31, Major products/services lines 2023 2022 Hardware 1,160 761 Consumables 209 257 Contract research services 86 196 Agrochem Products 181 165 Sample preparation accessories 133 132 Technical support/extended service contracts 156 174 Shipping and handling 45 42 Other 8 2 1,978 1,729 In thousands of US dollars ($) Year Ended December 31, Timing of revenue recognition 2023 2022 Transferred at a point in time 1,736 1,359 Transferred over time 242 370 1,978 1,729 Contract Balances Schedule of Contract Balances In thousands of US dollars ($) December 31, 2023 December 31, 2022 Receivables, which are included in ‘Accounts Receivable’ 151 295 Contract liabilities (deferred revenue) 34 60 Transaction price allocated to the remaining performance obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2024 2025 Total Extended warranty service 29 5 34 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing. v. Cash and Cash Equivalents Our policy is to invest available cash in short-term, investment grade interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair value, and are classified as cash equivalents. vi. Research and Development Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits, facilities, consumable products and overhead costs that are expensed as incurred. In support of our research and development activities we utilize our Barocycler instruments that are capitalized as fixed assets and depreciated over their expected useful life. vii. Inventories Inventories are valued at the lower of cost (average cost) or net realizable value. The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: Schedule of Inventories 2023 2022 Raw materials $ 63,950 $ 188,587 Finished goods 1,262,771 1,480,769 Inventory reserve (1,021,812 ) (982,973 ) Total $ 304,909 $ 686,383 viii. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of three years for certain laboratory equipment, from three to five years for management information systems and office equipment, and three years for all PCT finished units classified as fixed assets. ix. Intangible Assets We have classified as intangible assets, costs associated with the fair value of acquired intellectual property. Intangible assets, including patents, are being amortized on a straight-line basis over nine years. We perform an annual review of our intangible assets for impairment. We capitalize any costs to renew or extend the term of our intangible assets. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. The Company recognized impairment of $ 230,770 and none for the year ended December 31, 2023 and 2022, respectively . As of December 31, 2023, and 2022, the outstanding balance for intangible assets was $ 0 and $ 317,308 , respectively. x. Long-Lived Assets The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of the FASB ASC 360-10-05, Property, Plant, and Equipment xi. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected. At December 31, 2023, we determined that no allowance against accounts receivable was necessary. The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: Schedule of Customer Concentration Risk Percentage 2023 2022 Top Five Customers 43 % 24 % Federal Agencies 4 % 0 % One customer, our Chinese distributor, accounted for greater than 10 The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2023 2022 Top Five Customers 96 % 93 % Federal Agencies 0 % 0 % Three customers accounted for greater than 10 Investment in Equity Securities As of December 31, 2023 and 2022, we held 100,250 We had exchanged 33,334 100,250 As of December 31, 2023, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs, of our investment in Nexity to be $ 61,876 (1,762) As of December 31, 2022, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs, of our investment in Nexity to be $ 63,638 3,662 xii. Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, warrants to acquire preferred stock convertible into common stock, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive. The following table illustrates our computation of loss per share for the years ended December 31: Schedule of Computation of Loss Per Share 2023 2022 Numerator: Net loss attributable to common shareholders $ (35,202,434 ) $ (17,803,953 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 23,336,620 11,058,356 Loss per common share - basic and diluted $ (1.51 ) $ (1.61 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2023 2022 Stock options 4,920,754 1,307,822 Convertible debt 8,684,223 6,915,754 Common stock warrants 15,577,354 16,278,769 Convertible preferred stock: Series D Convertible Preferred 6,250 25,000 Series G Convertible Preferred - 26,857 Series H Convertible Preferred - 33,334 Series H2 Convertible Preferred - 70,000 Series J Convertible Preferred - 115,267 Series K Convertible Preferred - 229,334 Series AA Convertible Preferred 8,645,000 8,645,000 Series BB Convertible Preferred 12,190,000 - Series CC Convertible Preferred 4,010,000 - Total potentially dilutive shares 54,033,581 33,647,137 xiii. Accounting for Income Taxes We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in the Company’s ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be significant limitations on the amount of net loss carry forwards that could be used to offset future taxable income. Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2023 and 2022, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued on December 31, 2023 and 2022. xiv. Accounting for Stock-Based Compensation We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize equity compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Employee and non-employee awards are accounted for under ASC 718 where the awards are valued at grant date. Determining Fair Value of Stock Option Grants Valuation and Amortization Method Expected Term Compensation-Stock Compensation Expected Volatility Risk-Free Interest Rate Forfeitures Compensation-Stock Compensation The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2023 (there were no options granted in 2022): Summary of Assumptions for the Grants of Stock Options Assumptions CEO, other Expected life 6.0 (yrs) Expected volatility 155.02 % Risk-free interest rate 0.62 % Forfeiture rate 5.00 % Expected dividend yield 0.0 % We recognized stock-based compensation expense of $ 2,636,443 and $ 215,098 for the years ended December 31, 2023 and 2022, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items within our accompanying consolidated statements of operations for the years ended December 31: Schedule of Stock Based Compensation Expense 2023 2022 Research and development $ 536,244 $ 79,891 Selling and marketing 155,142 24,687 General and administrative 1,945,057 110,520 Total stock-based compensation expense $ 2,636,443 $ 215,098 During the years ended December 31, 2023 and December 31, 2022, the total fair value of stock options awarded was $ 4,090,508 0 As of December 31, 2023, total unrecognized compensation cost related to the unvested stock-based awards was $ 373,532 2.04 As of December 31, 2022, total unrecognized compensation cost related to the unvested stock-based awards was $ 15,312 1.09 xv. Advertising Advertising costs are expensed as incurred. We incurred $ 342 487 xvi. Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates. xvii. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ASC 820 The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are currently classified within Level 1. The Company does not have any financial liabilities that are required to be measured on a recurring basis at December 31, 2023 and 2022. The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2023: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at December 31, 2023 Quoted Significant Significant Equity Securities $ 61,876 61,876 - - Total Financial Assets $ 61,876 $ 61,876 $ - $ - The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2022: Fair value measurements at December 31, 2022 using: December 31, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 63,638 $ 63,638 - - Total Financial Assets $ 63,638 $ 63,638 $ - $ -

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, net	(4) Property and Equipment, net Property and equipment as of December 31, 2023 and 2022 consisted of the following components: Schedule of Property and Equipment 2023 2022 December 31, 2023 2022 Laboratory and manufacturing equipment $ 381,627 $ 374,132 Office equipment 194,999 194,999 Leasehold improvements 25,248 25,248 PCT collaboration, demonstration and leased systems 53,098 53,098 Total property and equipment 654,972 647,477 Less accumulated depreciation (570,042 ) (544,126 ) Net book value $ 84,930 $ 103,351 Depreciation expense for the years ended December 31, 2023 and 2022 was $ 25,916 33,250

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	(5) Intangible Assets Intangible assets as of December 31, 2023, reflect the purchase price attributable to patents received in connection with the acquisition of assets of BaroFold Corp. Acquired BaroFold patents are being amortized to expense on a straight line basis at the rate of $ 80,000 9 80,000 230,770 Schedule of Intangible Assets 2023 2022 December 31, 2023 2022 BaroFold Patents $ 750,000 $ 750,000 Less accumulated amortization and impairment (750,000 ) (432,692 ) Net book value $ - $ 317,308 Amortization expense for each of the years ended December 31, 2023 and 2022 was $ 86,538

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Retirement Plan	(6) Retirement Plan We provide all our employees with the opportunity to participate in our retirement savings plan. Our retirement savings plan has been qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the plan through payroll deductions within statutory limitations and subject to any limitations included in the plan. During 2023 and 2022 we contributed $ 10,792 12,777

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	(7) Income Taxes Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. On December 31, 2023 and 2022, the Company did not have any uncertain tax positions. No Significant items making up the deferred tax assets and deferred tax liabilities as of December 31, 2023 and 2022 are as follows: Schedule of Deferred Tax Assets and Deferred Tax Liabilities 2023 2022 Long term deferred taxes: Inventory reserve $ 300,254 $ 268,548 Other accruals 1,170,640 99,362 Other 89,474 15,715 Non-cash, stock-based compensation, nonqualified 2,533,983 872,967 Impairments 167,656 104,609 Operating loss carry forwards and tax credits 36,324,508 31,026,899 Less: valuation allowance (40,586,515 ) (32,388,100 ) Total net deferred tax assets $ - $ - A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. Accordingly, we established a valuation allowance in 2023 and 2022 for the full amount of our deferred tax assets for the uncertainty of realization. We believe that based on our projection of future taxable operating income for the foreseeable future, it is more likely than not that we will not be able to realize the benefit of the deferred tax asset at December 31, 2023. We have net operating loss carry-forwards for federal income tax purposes of approximately $ 129,304,842 2024 through 2038 Under the Tax Reform Act, NOL’s generated after December 31, 2017 can offset only 80% of a corporation’s taxable income in any year 91,016,166 We have research and development tax credit carryforwards for federal income tax purposes of approximately $ 2,288,308 381,425 The following table reconciles the U.S. Federal statutory tax rate to the Company’s effective tax rate: Schedule of U.S. Federal Statutory Tax Rate to Effective Income Tax Rate 2023 2022 Statutory U.S. Federal tax rate 21 % 21 % Permanent differences (0 ) (0 ) State tax expense (0 ) (0 ) Refundable AMT and R&D tax credit (0 ) (0 ) Valuation allowance (21 ) (21 ) Effective tax rate 0 % 0 %

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(8) Commitments and Contingencies Operating Leases The Company accounts for its leases under ASC 842. The Company has elected to apply the short-term lease exception to leases of one year or less. Through the end of 2023, our corporate office was located at 14 Norfolk Avenue, South Easton, Massachusetts, 02375. We were paying $ 7,650 We extended our lease for our space in Medford, MA (the “Medford Lease”) from December 30, 2020 to December 30, 2023. The lease required monthly payments of $ 7,282 The lease shall be automatically extended for three years unless either party terminates at least six months prior to the expiration of the current lease term. 221,432 12 On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term The Company accounted for the Sparks Lease as an operating lease under ASC 842. Upon the commencement of the lease, the Company recorded a right-of-use asset and lease liability in the amount of $ 239,327 12% Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms for greater than one year as of December 31, 2023: Schedule of Future Minimum Rental Payments Year Total 2024 $ 64,393 2025 $ 66,969 2026 $ 51,778 Total future undiscounted lease payments $ 183,140 Less: Imputed interest (55,284 ) Present value of lease liabilities 127,856 The operating cash flows from the operating leases were $ 154,239 113,470 Below is a table for the right of use asset and the corresponding lease liability in the consolidated balance sheets: Schedule of Right of Use Asset and the Corresponding Lease Liability Operating Leases December 31, 2023 December 31, 2022 Right of use asset $ 142,815 $ 282,095 Right of use lease liability, current $ 66,895 $ 142,171 Right of use lease liability, long term $ 60,961 $ 139,924 Total lease liability $ 127,856 $ 282,095 The weighted-average remaining lease term (years) of the above leases is 2.75 2.96 12% The Company had no financing lease during the year ended December 31, 2023 and 2022. The components of lease cost for operating leases for the years ended December 31, 2023 and 2022 are as follows: Schedule of Lease Cost for Operating Leases December 31, 2023 December 31, 2022 Operating lease cost $ 124,606 $ 151,239 Short-term lease cost 91,800 91,800 Total lease cost $ 216,406 $ 243,039 Battelle Memorial Institute In December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“ Battelle 1,200 2,000 3,000 4,000 5,000 Target Discovery Inc . In March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (“TDI”), a related party. Under the terms of the agreement, we have been licensed by TDI to manufacture and sell a highly innovative line of chemicals used in the preparation of tissues for scientific analysis (“TDI reagents”). The TDI reagents were designed for use in combination with our pressure cycling technology. The companies believe that the combination of PCT and the TDI reagents can fill an existing need in life science research for an automated method for rapid extraction and recovery of intact, functional proteins associated with cell membranes in tissue samples. We did not incur any royalty obligation under this agreement in 2023 or 2022. In April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We executed an amendment to this agreement on October 1, 2016 wherein we agreed to pay a monthly fee of $ 1,400 2,000 60,000 60,000 67,100 69,300 Severance and Change of Control Agreements Each of Mr. Schumacher, and Drs. Ting, and Lazarev, executive officers of the Company, are entitled to receive a severance payment if terminated by us without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental insurance coverage for one year following the date of termination. Each of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in the event of their termination upon a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general, and particularly in the occurrence of a change in control, as a disincentive to the control change.

Debt

Debt	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Debt	(9) Debt Convertible Debt On various dates during the year ended December 31, 2023, the Company issued convertible notes for net proceeds of approximately $ 5.5 1 12 0 18% 2.50 790,975 563,441 1,051,000 2,742,409 2,507,055 On various dates during the year ended December 31, 2022, the Company issued convertible notes for net proceeds of approximately $ 4.9 1 12 0 18% 2.50 873,854 93,576 541,313 1,522,494 1,694,028 The summary of specific terms of the convertible notes and outstanding balances as of December 31, 2023 and December 31, 2022 are listed in the tables below. The convertible notes are from numerous parties and with original issue dates from June, 2019 to December, 2023, and maturity dates from March, 2020 to December, 2024 13 Schedule of Convertible Debts and Outstanding Balances December 31, 2023 December 31, 2022 Holders Interest Rate Conversion Price Principal Interest Rate Conversion Price Principal Main Investor 10 % $ 2.50 (1) $ 8,920,250 10 % $ 2.50 (1) $ 9,393,150 Others 0 24 % $ 2.50 (2) or $ 7.50 12,409,062 0 24 % $ 7.50 (2) 8,886,036 Totals 21,329,312 18,279,186 Discount 645,471 455,517 Net $ 20,683,841 $ 17,823,669 Notes: (1) Conversion price of these note is $ 2.50 except for a note for $ 189,750 , which will be adjusted to, upon an Event of Default, the lower of (i) the conversion price or (ii) a 25 discount to the 5-day average VWAP of the stock prior to default, and $ 1,062,600 2.50 (2) Conversion price of these notes is $ 2.50 a. Notes are convertible before maturity at $ 2.50 2.50 b. Notes are convertible upon an Event of Default at 75% c. Notes are convertible at $ 2.50 75% d. Notes can be voluntary converted at lower of 1) $ 2.50 2.50 2.50 30% e. Notes can be voluntary converted at lower of 1) $ 2.50 2.50 2.50 25% f. Conversion price is lower of (i) $ 2.50 g. Note can be converted at a Voluntary Conversion Price which is the lower of 1) $ 2.50 2.50 70% h. Conversion price is $ 2.50 1 i. Notes can be voluntarily converted before maturity at $ 2.50 2.50 10% j. Notes can be converted at the lesser of $ 2.5 25% 35% k. Some notes are not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan with a principal balance of $ 950,000 l. Some notes can be converted at the lesser of $ 2.50 25% 5 m. Some notes can be converted at $ 2.50 60 n. Some notes can be converted at $2.50 through fixed rate expiration dates; thereafter lesser of (1) lowest trading price during the prior 25 days of the note or 65% of the lowest price during the 25 days prior to the conversion. Notes can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold by PBI at a price lower than $2.50/share. Notes can be voluntary converted at lower of lower of (i) $2.5/share and (ii) purchase Price of stock sold by PBIO at a price lower than $2.50/share that is not an Excluded Event in the Series AA Deal Documents. Notes can be converted at lower of lower of (i) $2.50 or (ii) the conversion price of the Series AA Preferred Stock as adjusted. Notes can be converted at lower of (i) $2.50 or (ii) the purchase price of stock by Series AA Holders. Notes can be voluntary converted at offering price of Common Stock at the close of the day prior to the Conversion Date As of December 31, 2023, the approximate principal balance that are secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. is $ 352,188 During the year ended December 31, 2023, the Company extended 23 loans totaling $ 5,625,648 6,325,263 2,552,300 802 Standstill and Forbearance Agreements The Company has entered into Standstill and Forbearance Agreements with lenders who hold variable-rate convertible notes with a total principal as of December 31, 2023 of $ 272,500 . Pursuant to the Standstill and Forbearance Agreements, the lenders agreed to not convert any portion of their notes into shares of common stock at a variable rate until April 16, 2021. During the year ended December 31, 2023, the Company settled one note with total principal of $ 302,484 , leaving one final lender (three notes) with total principal of $ 272,500 outstanding and incurred interest, penalties and fees of approximately $ 253,425 in connection with the Standstill and Forbearance Agreement. During the year ended December 31, 2022 the Company settled one note with a total principal of $ 166,703 and incurred interest, penalties, and fees of approximately $ 0.8 million in connection with the Standstill and Forbearance agreements. Convertible Loan Modifications and Extinguishments We refinanced certain convertible loans during the years ended December 31, 2023 and 2022 at substantially the same terms for extensions ranging over a period of three to twelve (12) months. We amortized any remaining unamortized debt discount as of the modification date over the remaining, extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments which were modified during the period or those settled with new notes issued concurrently for the same amounts but different maturity dates. The terms such as the interest rate, prepayment penalties, and default rates will be the same over the new extensions. According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications. The cash flows of new debt exceeded 10 751,335 3,970,983 Other Debt Twelve notes in Other Debt are past due as of December 31, 2023. Schedule of Other Debt December 31, 2023 December 31, 2022 Holders Interest Rate Principal Interest Rate Principal Non-Convertible - ) $ 170,000 - ) $ 878,809 Merchant debt (3) 1,094,162 760,160 SBA (2) 3.75 % 161,864 3.75 % 150,000 Totals 1,426,026 $ 1,788,969 Long Term 161,864 150,000 Short Term $ 1,264,162 $ 1,638,969 Notes: (1) Interest varies from 1 to 10 . The maturity is between being past due and May 2, 2023 . (2) The Company entered into a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $ 150,000 3.75% 731 367,039 1 367,039 (3) During the years ended December 31, 2023 and 2022 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 4.1 100.9 maturity dates ranged from July, 2023 to October, 2024. maturity dates ranged from April 4, 2023 to June 6, 2023. (4) Interest rate of 10 maturity date is December 31, 2019 651,500 170,000 Related Party Debt Schedule of Related Party Debt December 31, 2023 December 31, 2022 Holders Interest Rate Principal Interest Rate Principal Security Officers & Directors - ) $ 522,450 - ) $ 521,950 Unsecured Other Related Parties 12 % 126,050 12 % 120,850 Unsecured Totals 648,500 642,800 Discount - 7,915 Net $ 648,500 $ 634,885 Notes: (1) Interest varies from 12 120 During the year ended December 31, 2023, we received short-term non-convertible loans of $ 190,000 8,300 168,085 12% 120% During the year ended December 31, 2022, we received short-term non-convertible loans of $ 958,100 with $ 91,750 OID from related parties and repaid $ 315,300 of related party loans. These notes bear interest ranging from 12% to 120% interest and are due upon demand. All related party notes are convertible at $ 2.50 We amortized $ 8,300 83,835 0 7,915

Stockholders_ (Deficit)

Stockholders’ (Deficit)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Stockholders’ (Deficit)	(10) Stockholders’ (Deficit) Preferred Stock We are authorized to issue 1,000,000 0.01 As of December 31, 2023, there were no shares of Junior A issued and outstanding and no shares of Series A, B, C, G, H, H2, J and K issued and outstanding and as of December 31, 2022, there were no shares of Junior A issued and outstanding, and no shares of Series A, B, C, and E issued and outstanding. Below is a summary table of the preferred stock: Summary of Preferred Stock December 31, 2023 December 31, 2022 Series D Convertible Preferred Stock, $ .01 850 75 300 300,000 $ - $ 3 Series G Convertible Preferred Stock, $ .01 240,000 no 80,570 - 806 Series H Convertible Preferred Stock, $ .01 10,000 no 10,000 - 100 Series J Convertible Preferred Stock, $ .01 6,250 no 3,458 - 35 Series K Convertible Preferred Stock, $ .01 15,000 no 6,880 - 68 Series AA Convertible Preferred Stock, $ .01 10,000 8,645 86 86 Series BB Convertible Preferred Stock, $ .01 1,000 1,219 (1) no 12 - Series CC Convertible Preferred Stock, $ .01 2,000 401 no 4 - Series H2 Convertible Preferred Stock, $ .01 21 no 21 - - Series A Junior Participating Preferred Stock, $ .01 20,000 no - - Series A Convertible Preferred Stock, $ .01 313,960 no - - Series B Convertible Preferred Stock, $ .01 279,256 no - - Series C Convertible Preferred Stock, $ .01 88,098 no - - Series E Convertible Preferred Stock, $ .01 500 no - - Total Convertible Preferred Shares $ 102 $ 1,098 (1) 219 1,000,000 Series D Convertible Preferred Stock On November 11, 2011, we completed a registered direct offering, pursuant to which we sold an aggregate of 843 1,000 843,000 Series D Placement Series D Unit 0.01 Series D Convertible Preferred Stock 84 five 21 24.30 Series D Warrant The Series D Convertible Preferred Stock will rank senior to the Company’s common stock with respect to payments made upon liquidation, winding up or dissolution. Upon any liquidation, dissolution or winding up of the Company, after payment of the Company’s debts and liabilities, and before any payment is made to the holders of any junior securities, the holders of Series D Convertible Preferred Stock will first be entitled to be paid $ 1,000 We may not pay any dividends on shares of common stock unless we also pay dividends on the Series D Convertible Preferred Stock in the same form and amount, on an as-if-converted basis, as dividends actually paid on shares of our common stock. Except for such dividends, no other dividends may be paid on the Series D Convertible Preferred Stock. Each share of Series D Convertible Preferred Stock is convertible into 84 19.50 Series D Conversion Ratio 300 50,000 In addition, in the event we consummate a merger or consolidation with or into another person or other reorganization event in which our shares of common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license or otherwise dispose of all or substantially all of our assets or we or another person acquire 50 The holders of Series D Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except that the holders of Series D Convertible Preferred Stock may vote separately as a class on any matters that would (i) amend, our Restated Articles of Organization, as amended, in a manner that adversely affects the rights of the Series D Convertible Preferred Stock, (ii) alter or change adversely the powers, preferences or rights of the Series D Convertible Preferred Stock or alter or amend the certificate of designation, (iii) authorize or create any class of shares ranking as to dividends, redemption or distribution of assets upon liquidation senior to, or otherwise pari passu with, the Series D Convertible Preferred Stock, or (iv) increase the number of authorized shares of Series D Convertible Preferred Stock. If, within 12 months of the initial issuance of the Series D Convertible Preferred Stock, we issue any common stock, common stock equivalents, indebtedness or any combination thereof (a “ Subsequent Financing the holders of Series D Convertible Preferred Stock will have the right to participate on a pro-rata basis in up to 50% of such Subsequent Financing Series D Warrants All of these warrants have expired. Series AA Convertible Preferred Stock and Warrants During the year ended December 31, 2021, the Company entered into Securities Purchase Agreements with investors pursuant to which the Company sold an aggregate of 406 1,000 0.01 1,015,000 406,000 3.50 509,130 200 200,100 five year 3.50 245,635 23,004 During the year ended December 31, 2022, there was 4,400 1,727,275 1,658,175 The issuances of our convertible preferred stock and common stock purchase warrants are accounted for under the fair value and relative fair value method. The warrant is first analyzed per its terms as to whether it has derivative features or not. If the warrant is determined to be a derivative, then it is measured at fair value using the Black Scholes Option Model and recorded as a liability on the balance sheet. The warrant is re-measured at its then current fair value at each subsequent reporting date (it is “marked-to-market”). If the warrant is determined to not have derivative features, it is recorded into equity at its fair value using the Black Scholes option model, however, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the convertible preferred stock. We analyzed these warrants issued in 2021 and determined that they were not considered derivatives and therefore recorded the aggregate relative fair value of $ 509,130 406,000 The convertible preferred stock is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible preferred stock is examined for any intrinsic beneficial conversion feature (“BCF”) of which the convertible price of the preferred stock is less than the closing stock price on date of issuance. If the relative fair value method is used to value the convertible preferred stock and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares of common stock the convertible preferred stock is converted into by its terms. The adjusted BCF value of $ 0 873,798 On May 1, 2023, Pressure Biosciences, Inc. (the “Company”) filed Articles of Amendment to Restated Articles of Organization (the “Amendment”) with the Secretary of the Commonwealth of Massachusetts to designate 1,000 0.01 2,000 0.01 Series BB Preferred Stock Rank 0.01 Dividends Voting Rights The holders of Series BB Preferred Stock shall have the right to vote along with the holders of Common Stock in an amount equal to 10,000 votes for each share of Series BB Preferred Stock held. Voluntary Conversion 10,000 Company Forced Conversion 300% 2.50 Series CC Preferred Stock Rank Quarterly Dividends 8% Junior Stock Dividends Class Voting Rights 10% 75% 50% General Voting Rights Liquidation Preference 25,000.00 Voluntary Conversion 2.50 Company Forced Conversion 300% 10 Conversion Restriction 4.99% During the twelve months ended December 31, 2023 the Company converted 245 shares of Series BB convertible preferred stock and had 1,219 shares of Series BB convertible preferred stock outstanding which is 219 shares above the authorized of 1,000. As a result, 219 Series BB shares with an approximately fair value of $ 1,000,000 ● 233 1,360,867 ● 822 3,071,914 397,384 ● 128 563,441 ● 220 602,616 ● 245 62 ● 401 10,017,208 Common Stock Stock Options and Warrants On April 13, 2023, the Board authorized a 3-year extension of common stock warrants held by Series AA preferred shares holders. Therefore, 8,897,603 3,626,950 At the Company’s December 30, 2021 Special Meeting, the shareholder’s approved the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to which 3,000,000 4,920,754 All of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price at time of issuance. On October 18, 2023, the company’s board of directors approved the re-pricing of all issued and outstanding qualified and non-qualified stock option grants to $ 0.25 As of December 31, 2022, total unrecognized compensation cost related to the unvested stock-based awards was $ 15,312 1.09 1.30 0 1.53 The following tables summarize information concerning options and warrants outstanding and exercisable: Schedule of Options and Warrants Outstanding and Exercisable Stock Options Warrants Total Shares Weighted Shares Weighted Shares Exercisable Balance outstanding, December 31, 2021 1,333,101 $ 0.72 16,207,108 $ 3.50 17,540,209 17,308,567 Granted - - 277,500 3.50 277,500 - Exercised (25,279 ) 0.69 - - (25,279 ) Expired - - (205,839 ) 3.50 (205,839 ) Balance outstanding, December 31, 2022 1,307,822 $ 0.72 16,278,769 $ 3.50 17,586,591 17,570,591 Granted 7,151,238 0.25 100,000 3.50 7,251,238 - Exercised (117,552 ) 0.69 - - (117,552 ) Expired - - (801,415 ) 3.50 (645,829 ) Forfeited (3,420,754 ) - - - (3,420,754 ) Balance outstanding, December 31, 2023 4,920,754 $ 0.25 15,577,354 $ 3.50 20,628,305 18,625,326 Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Number of Remaining Exercise Number of Remaining Exercise $ 0.25 $ 1.00 4,920,754 8.5 $ 0.25 3,047,972 7.8 $ 0.25 $ 1.01 $ 3.00 - - $ - - - $ - 4,920,754 8.5 $ 0.25 3,047,972 7.8 $ 0.25 Common Stock Issuances For the year ended December 31, 2023 the Company recognized 117,552 shares issued with a fair value of $ 81,111 for stock option exercises; issued 2,150,000 shares for services rendered with a fair value of $ 2,082,544 ; 2,552,300 shares with a fair value of $ 2,028,748 for debt extensions; 203,613 shares with a fair value of $ 509,033 for conversion of debt and interest; 729,571 shares with a fair value of $ 386,936 for dividends paid in kind; 11,878,135 shares with a fair value of $ 8,226,186 for interest paid-in-kind; 1,625,642 shares for stock issued with debt with a fair value of $ 790,975 , 60,000 shares with a fair value of $ 150,000 for sale of common stock, 2,454,000 624,000 62 537,940 For the year ended December 31, 2022 the Company recognized 25,279 17,443 255,500 392,175 1,423,800 2,198,861 181,918 467,092 4,400 236,221 386,300 1,766,266 2,943,139 659,000 873,854 10,000 25,000 During the year ended December 31, 2023, the Company accrued approximately $ 5.3 2.7 For our loan dated December 23, 2020, we are obligated to issue 100,000 warrants if the loan is not repaid before January 23, 2021 and an additional 10,000 shares of common stock and 100,000 warrants if the loan is not repaid before February 23, 2021. We are also obligated to issue 10,000 shares of common stock and 200,000 warrants if the loan is not repaid before March 23, 2021. During the year ended December 31, 2021 the Company issued 400,000 3.50 600,298 10,000 For the twelve months ended December 31, 2023, the Company issued 100,000 warrants (four-year term at a $3.50 exercise price) to acquire common stock at a fair value of $ 61,609 to a consultant for professional services. For the twelve months ended December 31, 2022, the Company issued a total of 277,500 280,608 3.50 3 5 ● 120,000 93,576 ● 100,000 132,537 ● 57,500 54,495

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	(11) Subsequent Events Acquisition of Assets and Liabilities from CBH International LLC, dba “Uncle Bud’s.” On January 9, 2024, Pressure BioSciences, Inc. (the “Company”) and CBH International LLC, dba “Uncle Bud’s,” (“Uncle Bud’s”) signed an Asset Purchase Agreement (the “Agreement”) for the Company to acquire all of Uncle Bud’s assets and assume selected liabilities, including a $ 734,000 127 2,540,000 4,000,000 8,000,000 0.30 100% ten-year Debt, Preferred, Common Stock, and Option activity From January 1, 2024, through May 31, 2024, the Company issued thirteen ( 13 ) convertible loans for approximately $ 3,100,000 , which each carry a 0 - 72% annual interest rate and one ( 1 ) to twelve ( 12 ) month terms. All the loans are convertible into common stock either at $2.50 per share or subject to a conversion adjustment. The Company also repaid 6 loans totaling $ 272,852 22 7,281,000 880 353,000 From January 1, 2024, through June 6, 2024, 722 7,224,000 323 745 123 1,091 From January 1, 2024, through June 6, 2024, 1,053,250 1,274,000 From January 1, 2024, through June 6, 2024, 803,750 0.30 10 Lease On February 5, 2024, our corporate office and R&D labs have been consolidated into one facility and we are currently located at 480 Neponset St., Unit 10B, Canton, Massachusetts 02021. The lease agreement term is five years and contains escalating payments during the lease period with the first lease payment being due on May 1, 2024 and monthly rent ranging from $ 11,651 13,678

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Principles of Consolidation	i. Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	ii. Use of Estimates To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.
Recent Accounting Pronouncement	iii Recent Accounting Pronouncement In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires measurement and recognition of expected credit losses for financial assets held. We adopted this new accounting guidance effective January 1, 2023. The adoption did not have a material impact on our consolidated financial statements and disclosures and did not significantly impact the Company’s accounting policies or estimation methods related to the allowance for doubtful accounts. The Company does not have any reserve for doubtful accounts due to its customers being distributors, universities, research organizations and government agencies. In the past several years, all its customers have paid in full without any need for a write-down. In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $ 2,728,243 2,255,216 473,027
Revenue Recognition	iv. Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. Most of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold, which were nominal in 2023 and 2022. We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Revenue from government grants is recorded when expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. [REFER TO 10K TABLES WORK BOOK – REV DETAIL TAB] Schedule of Disaggregation of Revenue In thousands of US dollars ($) Year Ended December 31, Primary geographical markets 2023 2022 North America 1,366 1,191 Europe 136 144 Asia 476 394 1,978 1,729 In thousands of US dollars ($) Year Ended December 31, Major products/services lines 2023 2022 Hardware 1,160 761 Consumables 209 257 Contract research services 86 196 Agrochem Products 181 165 Sample preparation accessories 133 132 Technical support/extended service contracts 156 174 Shipping and handling 45 42 Other 8 2 1,978 1,729 In thousands of US dollars ($) Year Ended December 31, Timing of revenue recognition 2023 2022 Transferred at a point in time 1,736 1,359 Transferred over time 242 370 1,978 1,729 Contract Balances Schedule of Contract Balances In thousands of US dollars ($) December 31, 2023 December 31, 2022 Receivables, which are included in ‘Accounts Receivable’ 151 295 Contract liabilities (deferred revenue) 34 60 Transaction price allocated to the remaining performance obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2024 2025 Total Extended warranty service 29 5 34 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing.
Cash and Cash Equivalents	v. Cash and Cash Equivalents Our policy is to invest available cash in short-term, investment grade interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair value, and are classified as cash equivalents.
Research and Development	vi. Research and Development Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits, facilities, consumable products and overhead costs that are expensed as incurred. In support of our research and development activities we utilize our Barocycler instruments that are capitalized as fixed assets and depreciated over their expected useful life.
Inventories	vii. Inventories Inventories are valued at the lower of cost (average cost) or net realizable value. The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: Schedule of Inventories 2023 2022 Raw materials $ 63,950 $ 188,587 Finished goods 1,262,771 1,480,769 Inventory reserve (1,021,812 ) (982,973 ) Total $ 304,909 $ 686,383
Property and Equipment	viii. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of three years for certain laboratory equipment, from three to five years for management information systems and office equipment, and three years for all PCT finished units classified as fixed assets.
Intangible Assets	ix. Intangible Assets We have classified as intangible assets, costs associated with the fair value of acquired intellectual property. Intangible assets, including patents, are being amortized on a straight-line basis over nine years. We perform an annual review of our intangible assets for impairment. We capitalize any costs to renew or extend the term of our intangible assets. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. The Company recognized impairment of $ 230,770 and none for the year ended December 31, 2023 and 2022, respectively . As of December 31, 2023, and 2022, the outstanding balance for intangible assets was $ 0 and $ 317,308 , respectively.
Long-Lived Assets	x. Long-Lived Assets The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of the FASB ASC 360-10-05, Property, Plant, and Equipment
Concentrations	xi. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected. At December 31, 2023, we determined that no allowance against accounts receivable was necessary. The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: Schedule of Customer Concentration Risk Percentage 2023 2022 Top Five Customers 43 % 24 % Federal Agencies 4 % 0 % One customer, our Chinese distributor, accounted for greater than 10 The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2023 2022 Top Five Customers 96 % 93 % Federal Agencies 0 % 0 % Three customers accounted for greater than 10 Investment in Equity Securities As of December 31, 2023 and 2022, we held 100,250 We had exchanged 33,334 100,250 As of December 31, 2023, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs, of our investment in Nexity to be $ 61,876 (1,762) As of December 31, 2022, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs, of our investment in Nexity to be $ 63,638 3,662
Computation of Loss per Share	xii. Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, warrants to acquire preferred stock convertible into common stock, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive. The following table illustrates our computation of loss per share for the years ended December 31: Schedule of Computation of Loss Per Share 2023 2022 Numerator: Net loss attributable to common shareholders $ (35,202,434 ) $ (17,803,953 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 23,336,620 11,058,356 Loss per common share - basic and diluted $ (1.51 ) $ (1.61 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2023 2022 Stock options 4,920,754 1,307,822 Convertible debt 8,684,223 6,915,754 Common stock warrants 15,577,354 16,278,769 Convertible preferred stock: Series D Convertible Preferred 6,250 25,000 Series G Convertible Preferred - 26,857 Series H Convertible Preferred - 33,334 Series H2 Convertible Preferred - 70,000 Series J Convertible Preferred - 115,267 Series K Convertible Preferred - 229,334 Series AA Convertible Preferred 8,645,000 8,645,000 Series BB Convertible Preferred 12,190,000 - Series CC Convertible Preferred 4,010,000 - Total potentially dilutive shares 54,033,581 33,647,137
Accounting for Income Taxes	xiii. Accounting for Income Taxes We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in the Company’s ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be significant limitations on the amount of net loss carry forwards that could be used to offset future taxable income. Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2023 and 2022, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued on December 31, 2023 and 2022.
Accounting for Stock-Based Compensation	xiv. Accounting for Stock-Based Compensation We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize equity compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Employee and non-employee awards are accounted for under ASC 718 where the awards are valued at grant date. Determining Fair Value of Stock Option Grants Valuation and Amortization Method Expected Term Compensation-Stock Compensation Expected Volatility Risk-Free Interest Rate Forfeitures Compensation-Stock Compensation The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2023 (there were no options granted in 2022): Summary of Assumptions for the Grants of Stock Options Assumptions CEO, other Expected life 6.0 (yrs) Expected volatility 155.02 % Risk-free interest rate 0.62 % Forfeiture rate 5.00 % Expected dividend yield 0.0 % We recognized stock-based compensation expense of $ 2,636,443 and $ 215,098 for the years ended December 31, 2023 and 2022, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items within our accompanying consolidated statements of operations for the years ended December 31: Schedule of Stock Based Compensation Expense 2023 2022 Research and development $ 536,244 $ 79,891 Selling and marketing 155,142 24,687 General and administrative 1,945,057 110,520 Total stock-based compensation expense $ 2,636,443 $ 215,098 During the years ended December 31, 2023 and December 31, 2022, the total fair value of stock options awarded was $ 4,090,508 0 As of December 31, 2023, total unrecognized compensation cost related to the unvested stock-based awards was $ 373,532 2.04 As of December 31, 2022, total unrecognized compensation cost related to the unvested stock-based awards was $ 15,312 1.09
Advertising	xv. Advertising Advertising costs are expensed as incurred. We incurred $ 342 487
Fair Value of Financial Instruments	xvi. Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates.
Fair Value Measurements	xvii. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ASC 820 The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are currently classified within Level 1. The Company does not have any financial liabilities that are required to be measured on a recurring basis at December 31, 2023 and 2022. The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2023: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at December 31, 2023 Quoted Significant Significant Equity Securities $ 61,876 61,876 - - Total Financial Assets $ 61,876 $ 61,876 $ - $ - The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2022: Fair value measurements at December 31, 2022 using: December 31, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 63,638 $ 63,638 - - Total Financial Assets $ 63,638 $ 63,638 $ - $ -

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of Disaggregation of Revenue	Schedule of Disaggregation of Revenue In thousands of US dollars ($) Year Ended December 31, Primary geographical markets 2023 2022 North America 1,366 1,191 Europe 136 144 Asia 476 394 1,978 1,729 In thousands of US dollars ($) Year Ended December 31, Major products/services lines 2023 2022 Hardware 1,160 761 Consumables 209 257 Contract research services 86 196 Agrochem Products 181 165 Sample preparation accessories 133 132 Technical support/extended service contracts 156 174 Shipping and handling 45 42 Other 8 2 1,978 1,729 In thousands of US dollars ($) Year Ended December 31, Timing of revenue recognition 2023 2022 Transferred at a point in time 1,736 1,359 Transferred over time 242 370 1,978 1,729
Schedule of Contract Balances	Contract Balances Schedule of Contract Balances In thousands of US dollars ($) December 31, 2023 December 31, 2022 Receivables, which are included in ‘Accounts Receivable’ 151 295 Contract liabilities (deferred revenue) 34 60
Schedule of Future Related to Performance Obligations	The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2024 2025 Total Extended warranty service 29 5 34
Schedule of Inventories	Inventories are valued at the lower of cost (average cost) or net realizable value. The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: Schedule of Inventories 2023 2022 Raw materials $ 63,950 $ 188,587 Finished goods 1,262,771 1,480,769 Inventory reserve (1,021,812 ) (982,973 ) Total $ 304,909 $ 686,383
Schedule of Customer Concentration Risk Percentage	The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: Schedule of Customer Concentration Risk Percentage 2023 2022 Top Five Customers 43 % 24 % Federal Agencies 4 % 0 % One customer, our Chinese distributor, accounted for greater than 10 The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2023 2022 Top Five Customers 96 % 93 % Federal Agencies 0 % 0 %
Schedule of Computation of Loss Per Share	Schedule of Computation of Loss Per Share 2023 2022 Numerator: Net loss attributable to common shareholders $ (35,202,434 ) $ (17,803,953 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 23,336,620 11,058,356 Loss per common share - basic and diluted $ (1.51 ) $ (1.61 )
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2023 2022 Stock options 4,920,754 1,307,822 Convertible debt 8,684,223 6,915,754 Common stock warrants 15,577,354 16,278,769 Convertible preferred stock: Series D Convertible Preferred 6,250 25,000 Series G Convertible Preferred - 26,857 Series H Convertible Preferred - 33,334 Series H2 Convertible Preferred - 70,000 Series J Convertible Preferred - 115,267 Series K Convertible Preferred - 229,334 Series AA Convertible Preferred 8,645,000 8,645,000 Series BB Convertible Preferred 12,190,000 - Series CC Convertible Preferred 4,010,000 - Total potentially dilutive shares 54,033,581 33,647,137
Summary of Assumptions for the Grants of Stock Options	The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2023 (there were no options granted in 2022): Summary of Assumptions for the Grants of Stock Options Assumptions CEO, other Expected life 6.0 (yrs) Expected volatility 155.02 % Risk-free interest rate 0.62 % Forfeiture rate 5.00 % Expected dividend yield 0.0 %
Schedule of Stock Based Compensation Expense	Schedule of Stock Based Compensation Expense 2023 2022 Research and development $ 536,244 $ 79,891 Selling and marketing 155,142 24,687 General and administrative 1,945,057 110,520 Total stock-based compensation expense $ 2,636,443 $ 215,098
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2023: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at December 31, 2023 Quoted Significant Significant Equity Securities $ 61,876 61,876 - - Total Financial Assets $ 61,876 $ 61,876 $ - $ - The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2022: Fair value measurements at December 31, 2022 using: December 31, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 63,638 $ 63,638 - - Total Financial Assets $ 63,638 $ 63,638 $ - $ -

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment as of December 31, 2023 and 2022 consisted of the following components: Schedule of Property and Equipment 2023 2022 December 31, 2023 2022 Laboratory and manufacturing equipment $ 381,627 $ 374,132 Office equipment 194,999 194,999 Leasehold improvements 25,248 25,248 PCT collaboration, demonstration and leased systems 53,098 53,098 Total property and equipment 654,972 647,477 Less accumulated depreciation (570,042 ) (544,126 ) Net book value $ 84,930 $ 103,351

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Schedule of Intangible Assets 2023 2022 December 31, 2023 2022 BaroFold Patents $ 750,000 $ 750,000 Less accumulated amortization and impairment (750,000 ) (432,692 ) Net book value $ - $ 317,308

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Deferred Tax Liabilities	Significant items making up the deferred tax assets and deferred tax liabilities as of December 31, 2023 and 2022 are as follows: Schedule of Deferred Tax Assets and Deferred Tax Liabilities 2023 2022 Long term deferred taxes: Inventory reserve $ 300,254 $ 268,548 Other accruals 1,170,640 99,362 Other 89,474 15,715 Non-cash, stock-based compensation, nonqualified 2,533,983 872,967 Impairments 167,656 104,609 Operating loss carry forwards and tax credits 36,324,508 31,026,899 Less: valuation allowance (40,586,515 ) (32,388,100 ) Total net deferred tax assets $ - $ -
Schedule of U.S. Federal Statutory Tax Rate to Effective Income Tax Rate	The following table reconciles the U.S. Federal statutory tax rate to the Company’s effective tax rate: Schedule of U.S. Federal Statutory Tax Rate to Effective Income Tax Rate 2023 2022 Statutory U.S. Federal tax rate 21 % 21 % Permanent differences (0 ) (0 ) State tax expense (0 ) (0 ) Refundable AMT and R&D tax credit (0 ) (0 ) Valuation allowance (21 ) (21 ) Effective tax rate 0 % 0 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments	Schedule of Future Minimum Rental Payments Year Total 2024 $ 64,393 2025 $ 66,969 2026 $ 51,778 Total future undiscounted lease payments $ 183,140 Less: Imputed interest (55,284 ) Present value of lease liabilities 127,856
Schedule of Right of Use Asset and the Corresponding Lease Liability	Below is a table for the right of use asset and the corresponding lease liability in the consolidated balance sheets: Schedule of Right of Use Asset and the Corresponding Lease Liability Operating Leases December 31, 2023 December 31, 2022 Right of use asset $ 142,815 $ 282,095 Right of use lease liability, current $ 66,895 $ 142,171 Right of use lease liability, long term $ 60,961 $ 139,924 Total lease liability $ 127,856 $ 282,095
Schedule of Lease Cost for Operating Leases	The components of lease cost for operating leases for the years ended December 31, 2023 and 2022 are as follows: Schedule of Lease Cost for Operating Leases December 31, 2023 December 31, 2022 Operating lease cost $ 124,606 $ 151,239 Short-term lease cost 91,800 91,800 Total lease cost $ 216,406 $ 243,039

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Convertible Debts and Outstanding Balances	Schedule of Convertible Debts and Outstanding Balances December 31, 2023 December 31, 2022 Holders Interest Rate Conversion Price Principal Interest Rate Conversion Price Principal Main Investor 10 % $ 2.50 (1) $ 8,920,250 10 % $ 2.50 (1) $ 9,393,150 Others 0 24 % $ 2.50 (2) or $ 7.50 12,409,062 0 24 % $ 7.50 (2) 8,886,036 Totals 21,329,312 18,279,186 Discount 645,471 455,517 Net $ 20,683,841 $ 17,823,669 Notes: (1) Conversion price of these note is $ 2.50 except for a note for $ 189,750 , which will be adjusted to, upon an Event of Default, the lower of (i) the conversion price or (ii) a 25 discount to the 5-day average VWAP of the stock prior to default, and $ 1,062,600 2.50 (2) Conversion price of these notes is $ 2.50 a. Notes are convertible before maturity at $ 2.50 2.50 b. Notes are convertible upon an Event of Default at 75% c. Notes are convertible at $ 2.50 75% d. Notes can be voluntary converted at lower of 1) $ 2.50 2.50 2.50 30% e. Notes can be voluntary converted at lower of 1) $ 2.50 2.50 2.50 25% f. Conversion price is lower of (i) $ 2.50 g. Note can be converted at a Voluntary Conversion Price which is the lower of 1) $ 2.50 2.50 70% h. Conversion price is $ 2.50 1 i. Notes can be voluntarily converted before maturity at $ 2.50 2.50 10% j. Notes can be converted at the lesser of $ 2.5 25% 35% k. Some notes are not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan with a principal balance of $ 950,000 l. Some notes can be converted at the lesser of $ 2.50 25% 5 m. Some notes can be converted at $ 2.50 60 n. Some notes can be converted at $2.50 through fixed rate expiration dates; thereafter lesser of (1) lowest trading price during the prior 25 days of the note or 65% of the lowest price during the 25 days prior to the conversion. Notes can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold by PBI at a price lower than $2.50/share. Notes can be voluntary converted at lower of lower of (i) $2.5/share and (ii) purchase Price of stock sold by PBIO at a price lower than $2.50/share that is not an Excluded Event in the Series AA Deal Documents. Notes can be converted at lower of lower of (i) $2.50 or (ii) the conversion price of the Series AA Preferred Stock as adjusted. Notes can be converted at lower of (i) $2.50 or (ii) the purchase price of stock by Series AA Holders. Notes can be voluntary converted at offering price of Common Stock at the close of the day prior to the Conversion Date
Schedule of Other Debt	Schedule of Other Debt December 31, 2023 December 31, 2022 Holders Interest Rate Principal Interest Rate Principal Non-Convertible - ) $ 170,000 - ) $ 878,809 Merchant debt (3) 1,094,162 760,160 SBA (2) 3.75 % 161,864 3.75 % 150,000 Totals 1,426,026 $ 1,788,969 Long Term 161,864 150,000 Short Term $ 1,264,162 $ 1,638,969 Notes: (1) Interest varies from 1 to 10 . The maturity is between being past due and May 2, 2023 . (2) The Company entered into a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $ 150,000 3.75% 731 367,039 1 367,039 (3) During the years ended December 31, 2023 and 2022 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 4.1 100.9 maturity dates ranged from July, 2023 to October, 2024. maturity dates ranged from April 4, 2023 to June 6, 2023. (4) Interest rate of 10 maturity date is December 31, 2019 651,500 170,000
Schedule of Related Party Debt	Schedule of Related Party Debt December 31, 2023 December 31, 2022 Holders Interest Rate Principal Interest Rate Principal Security Officers & Directors - ) $ 522,450 - ) $ 521,950 Unsecured Other Related Parties 12 % 126,050 12 % 120,850 Unsecured Totals 648,500 642,800 Discount - 7,915 Net $ 648,500 $ 634,885 Notes: (1) Interest varies from 12 120

Stockholders_ (Deficit) (Tables

Stockholders’ (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Summary of Preferred Stock	Below is a summary table of the preferred stock: Summary of Preferred Stock December 31, 2023 December 31, 2022 Series D Convertible Preferred Stock, $ .01 850 75 300 300,000 $ - $ 3 Series G Convertible Preferred Stock, $ .01 240,000 no 80,570 - 806 Series H Convertible Preferred Stock, $ .01 10,000 no 10,000 - 100 Series J Convertible Preferred Stock, $ .01 6,250 no 3,458 - 35 Series K Convertible Preferred Stock, $ .01 15,000 no 6,880 - 68 Series AA Convertible Preferred Stock, $ .01 10,000 8,645 86 86 Series BB Convertible Preferred Stock, $ .01 1,000 1,219 (1) no 12 - Series CC Convertible Preferred Stock, $ .01 2,000 401 no 4 - Series H2 Convertible Preferred Stock, $ .01 21 no 21 - - Series A Junior Participating Preferred Stock, $ .01 20,000 no - - Series A Convertible Preferred Stock, $ .01 313,960 no - - Series B Convertible Preferred Stock, $ .01 279,256 no - - Series C Convertible Preferred Stock, $ .01 88,098 no - - Series E Convertible Preferred Stock, $ .01 500 no - - Total Convertible Preferred Shares $ 102 $ 1,098 (1) 219 1,000,000
Schedule of Options and Warrants Outstanding and Exercisable	The following tables summarize information concerning options and warrants outstanding and exercisable: Schedule of Options and Warrants Outstanding and Exercisable Stock Options Warrants Total Shares Weighted Shares Weighted Shares Exercisable Balance outstanding, December 31, 2021 1,333,101 $ 0.72 16,207,108 $ 3.50 17,540,209 17,308,567 Granted - - 277,500 3.50 277,500 - Exercised (25,279 ) 0.69 - - (25,279 ) Expired - - (205,839 ) 3.50 (205,839 ) Balance outstanding, December 31, 2022 1,307,822 $ 0.72 16,278,769 $ 3.50 17,586,591 17,570,591 Granted 7,151,238 0.25 100,000 3.50 7,251,238 - Exercised (117,552 ) 0.69 - - (117,552 ) Expired - - (801,415 ) 3.50 (645,829 ) Forfeited (3,420,754 ) - - - (3,420,754 ) Balance outstanding, December 31, 2023 4,920,754 $ 0.25 15,577,354 $ 3.50 20,628,305 18,625,326
Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range	Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Number of Remaining Exercise Number of Remaining Exercise $ 0.25 $ 1.00 4,920,754 8.5 $ 0.25 3,047,972 7.8 $ 0.25 $ 1.01 $ 3.00 - - $ - - - $ - 4,920,754 8.5 $ 0.25 3,047,972 7.8 $ 0.25

Schedule of Disaggregation of R

Schedule of Disaggregation of Revenue (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Product Information [Line Items]
Revenue	$ 1,977,763	$ 1,729,343
Hardware [Member]
Product Information [Line Items]
Revenue	1,160,000	761,000
Consumables [Member]
Product Information [Line Items]
Revenue	209,000	257,000
Contract Research Services [Member]
Product Information [Line Items]
Revenue	86,000	196,000
Agrochem Products [Member]
Product Information [Line Items]
Revenue	181,000	165,000
Sample Preparation Accessories [Member]
Product Information [Line Items]
Revenue	133,000	132,000
Technical Support Extended Service Contracts [Member]
Product Information [Line Items]
Revenue	156,000	174,000
Shipping and Handling [Member]
Product Information [Line Items]
Revenue	45,000	42,000
Other [Member]
Product Information [Line Items]
Revenue	8,000	2,000
Transferred At A Point In Time [Member]
Product Information [Line Items]
Revenue	1,736,000	1,359,000
Transferred Over At Time [Member]
Product Information [Line Items]
Revenue	242,000	370,000
North America [Member]
Product Information [Line Items]
Revenue	1,366,000	1,191,000
Europe [Member]
Product Information [Line Items]
Revenue	136,000	144,000
Asia [Member]
Product Information [Line Items]
Revenue	$ 476,000	$ 394,000

Schedule of Contract Balances (

Schedule of Contract Balances (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Receivables, which are included in ‘Accounts Receivable’	$ 151	$ 295
Contract liabilities (deferred revenue)	$ 34	$ 60

Schedule of Future Related to P

Schedule of Future Related to Performance Obligations (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	$ 34
2024 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	29
2025 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	$ 5

Schedule of Inventories (Detail

Schedule of Inventories (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Raw materials	$ 63,950	$ 188,587
Finished goods	1,262,771	1,480,769
Inventory reserve	(1,021,812)	(982,973)
Total	$ 304,909	$ 686,383

Schedule of Customer Concentrat

Schedule of Customer Concentration Risk Percentage (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Top Five Customers [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration credit risk percentage	43%	24%
Top Five Customers [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration credit risk percentage	96%	93%
Federal Agencies [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration credit risk percentage	4%	0%
Federal Agencies [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration credit risk percentage	0%	0%

Schedule of Computation of Loss

Schedule of Computation of Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Net loss attributable to common shareholders	$ (35,202,434)	$ (17,803,953)
Weighted average common stock shares outstanding - basic	23,336,620	11,058,356
Weighted average common stock shares outstanding - diluted	23,336,620	11,058,356
Loss per common share - basic	$ (1.51)	$ (1.61)
Loss per common share - diluted	$ (1.51)	$ (1.61)

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	54,033,581	33,647,137
Employee Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	4,920,754	1,307,822
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	8,684,223	6,915,754
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	15,577,354	16,278,769
Series D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	6,250	25,000
Series G Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		26,857
Series H Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		33,334
Series H2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		70,000
Series J Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		115,267
Series K Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		229,334
Series AA Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	8,645,000	8,645,000
Series BB Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	12,190,000
Series CC Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	4,010,000

Summary of Assumptions for the

Summary of Assumptions for the Grants of Stock Options (Details) - Employees Officers [Member]	12 Months Ended
	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected life	6 years
Expected volatility	155.02%
Risk-free interest rate	0.62%
Forfeiture rate	5%
Expected dividend yield	0%

Schedule of Stock Based Compens

Schedule of Stock Based Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total stock-based compensation expense	$ 2,636,443	$ 215,098
Research and Development Expense [Member]
Total stock-based compensation expense	536,244	79,891
Selling and Marketing Expense [Member]
Total stock-based compensation expense	155,142	24,687
General and Administrative Expense [Member]
Total stock-based compensation expense	$ 1,945,057	$ 110,520

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Financing Receivable, Past Due [Line Items]
Total Financial Assets	$ 61,876	$ 63,638
Fair Value, Inputs, Level 1 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	61,876	63,638
Fair Value, Inputs, Level 2 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Fair Value, Inputs, Level 3 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Equity Securities [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	61,876	63,638
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	61,876	63,638
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Jan. 01, 2022	Dec. 31, 2021
Product Information [Line Items]
Cumulative effect of adoption, adjustment in additional paid in capital	$ 100,236,710	$ 69,006,145
Cumulative effect of adoption, adjustment in accumulated deficit	(169,028,639)	(133,826,205)
Stockholders deficit	(32,753,829)	(32,686,371)		$ (22,208,961)
Goodwill and Intangible Asset Impairment	230,770
Intangible Assets, Current	0	317,308
Stock-based compensation expense	2,636,443	215,098
Fair value of stock options awarded	4,090,508	0
Share-based payment arrangement, nonvested award, cost not yet recognized, amount	$ 373,532	$ 15,312
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition	2 years 14 days	1 year 1 month 2 days
Advertising costs	$ 342	$ 487
Everest [Member]
Product Information [Line Items]
Sale of stock number of shares received	100,250
Number of common stock shares exchanged during the period	33,334
Nexity Global SA [Member]
Product Information [Line Items]
Sale of stock number of shares received	100,250	100,250
Investment owned, at fair value	$ 61,876	$ 63,638
Unrealized gain	$ (1,762)	$ 3,662
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk percentage	10%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Three Customers [Member]
Product Information [Line Items]
Concentration risk percentage	10%
Cumulative Effect, Period of Adoption, Adjustment [Member]
Product Information [Line Items]
Cumulative effect of adoption, adjustment in additional paid in capital			$ 2,728,243
Cumulative effect of adoption, adjustment in accumulated deficit			2,255,216
Stockholders deficit			$ 473,027

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Laboratory and manufacturing equipment	$ 381,627	$ 374,132
Office equipment	194,999	194,999
Leasehold improvements	25,248	25,248
PCT collaboration, demonstration and leased systems	53,098	53,098
Total property and equipment	654,972	647,477
Less accumulated depreciation	(570,042)	(544,126)
Net book value	$ 84,930	$ 103,351

Property and Equipment, net (De

Property and Equipment, net (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 25,916	$ 33,250

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
BaroFold Patents	$ 750,000	$ 750,000
Less accumulated amortization and impairment	(750,000)	(432,692)
Net book value		$ 317,308

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 86,538	$ 86,538
Intangible assets amortization of straight line period	9 years
Amortization expense, year five	$ 80,000
Impairment of intangible assets	230,770	$ 230,770
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 80,000

Retirement Plan (Details Narrat

Retirement Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Retirement Benefits [Abstract]
Payment for pension benefits	$ 10,792	$ 12,777

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Long term deferred taxes:
Inventory reserve	$ 300,254	$ 268,548
Other accruals	1,170,640	99,362
Other	89,474	15,715
Non-cash, stock-based compensation, nonqualified	2,533,983	872,967
Impairments	167,656	104,609
Operating loss carry forwards and tax credits	36,324,508	31,026,899
Less: valuation allowance	(40,586,515)	(32,388,100)
Total net deferred tax assets

Schedule of U.S. Federal Statut

Schedule of U.S. Federal Statutory Tax Rate to Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Statutory U.S. Federal tax rate	21%	21%
Permanent differences	(0.00%)	(0.00%)
State tax expense	(0.00%)	(0.00%)
Refundable AMT and R&D tax credit	(0.00%)	(0.00%)
Valuation allowance	(21.00%)	(21.00%)
Effective tax rate	0%	0%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Unrecognized tax benefits, income tax penalties and interest accrued	$ 0	$ 0
Net operating loss	(9,503,358)	$ (4,898,289)	$ 91,016,166
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 129,304,842
Operating loss carry-forwards expire term	2024 through 2038
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Income tax examination, description	Under the Tax Reform Act, NOL’s generated after December 31, 2017 can offset only 80% of a corporation’s taxable income in any year
Deferred tax assets, tax credit carryforwards	$ 2,288,308
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Deferred tax assets, tax credit carryforwards	$ 381,425

Schedule of Future Minimum Rent

Schedule of Future Minimum Rental Payments (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
2024	$ 64,393
2025	66,969
2026	51,778
Total future undiscounted lease payments	183,140
Less: Imputed interest	(55,284)
Present value of lease liabilities	$ 127,856	$ 282,095

Schedule of Right of Use Asset

Schedule of Right of Use Asset and the Corresponding Lease Liability (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Right of use asset	$ 142,815	$ 282,095
Right of use lease liability, current	66,895	142,171
Right of use lease liability, long term	60,961	139,924
Total lease liability	$ 127,856	$ 282,095

Schedule of Lease Cost for Oper

Schedule of Lease Cost for Operating Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 124,606	$ 151,239
Short-term lease cost	91,800	91,800
Total lease cost	$ 216,406	$ 243,039

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
	Aug. 09, 2021	Apr. 30, 2012	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Right-of-use asset			$ 142,815	$ 282,095
Operating lease liability			127,856	282,095
Operating lease liability			60,961	139,924
Cash flow from operating leases			$ 154,239	$ 113,470
Weighted-average remaining lease term			2 years 9 months	2 years 11 months 15 days
Weighted-average discount rate			12%	12%
Expenses			$ 11,481,121	$ 6,627,632
Battelle Memorial Institute [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Mimimum royalty fee						$ 5,000	$ 4,000	$ 3,000	$ 2,000	$ 1,200
Target Discovery Inc [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Mimimum royalty fee				60,000	$ 60,000
Payments for fees		$ 1,400
Professional and contract services expense		$ 2,000
Expenses			67,100	$ 69,300
Medford Lease [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Annual cost of living payment			$ 7,282
Lessee operating lease description			The lease shall be automatically extended for three years unless either party terminates at least six months prior to the expiration of the current lease term.
Right-of-use asset			$ 221,432
Operating lease liability			$ 221,432
Estimated borrowing rate			12%
Sparks Lease [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lessee operating lease description	On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term
Right-of-use asset			$ 239,327
Estimated borrowing rate			12%
Operating lease liability			$ 239,327
Corporate Office [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lease monthly payments			$ 7,650

Schedule of Convertible Debts a

Schedule of Convertible Debts and Outstanding Balances (Details) - USD ($)		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Conversion price		$ 2.50
Totals		$ 21,329,312	$ 18,279,186
Totals		645,471	455,517
Totals		$ 20,683,841	$ 17,823,669
Debt instrument trading percent		60%
Investor [Member]
Debt Instrument [Line Items]
Interest Rate		10%	10%
Conversion price	[1]	$ 2.50	$ 2.50
Totals		$ 8,920,250	$ 9,393,150
Others [Member]
Debt Instrument [Line Items]
Conversion price	[2]		$ 7.50
Totals		$ 12,409,062	$ 8,886,036
Others [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest Rate		0%	0%
Conversion price	[2]	$ 2.50
Others [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest Rate		24%	24%
Conversion price		$ 7.50
[1]Conversion price of these note is $[2]Conversion price of these notes is $ 2.50

Schedule of Convertible Debts_2

Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2023 USD ($) Integer $ / shares
Short-Term Debt [Line Items]
Debt instrument, convertible price per shares	$ 2.50
Debt default amount | $	$ 1
Debt instrument, convertible, conversion price	$ 2.50
Debt default convertible conversion ratio	75%
Debt instrument, convertible, conversion price, Increase	$ 2.50
Debt instrument, convertible, conversion price, decrease	$ 2.50
Percentage of price	10%
Convertible lesser per share	$ 2.5
Convertible lesser Percent	25%
Original debt, interest rate of debt	35%
Principal balance | $	$ 13,000,000
Trading day | Integer	5
Debt instrument, convertible, conversion price	$ 2.50
Debt Conversion, Description	Some notes can be converted at $2.50 through fixed rate expiration dates; thereafter lesser of (1) lowest trading price during the prior 25 days of the note or 65% of the lowest price during the 25 days prior to the conversion. Notes can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold by PBI at a price lower than $2.50/share. Notes can be voluntary converted at lower of lower of (i) $2.5/share and (ii) purchase Price of stock sold by PBIO at a price lower than $2.50/share that is not an Excluded Event in the Series AA Deal Documents. Notes can be converted at lower of lower of (i) $2.50 or (ii) the conversion price of the Series AA Preferred Stock as adjusted. Notes can be converted at lower of (i) $2.50 or (ii) the purchase price of stock by Series AA Holders. Notes can be voluntary converted at offering price of Common Stock at the close of the day prior to the Conversion Date
Chief Executive Officer [Member]
Short-Term Debt [Line Items]
Principal balance | $	$ 950,000
Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible price per shares	$ 2.50
Debt default amount | $	$ 189,750
Debt instrument lowest trading price	25%
Convertible Debt [Member] | Series A A Preferred Stock [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible price per shares	$ 2.50
Convertible Debt [Member] | 5 Day Average VWAP [Member]
Short-Term Debt [Line Items]
Debt default amount | $	$ 1,062,600
Convertible Debt One [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible price per shares	$ 2.50
Convertible Debt Three [Member]
Short-Term Debt [Line Items]
Debt instrument lowest trading price	25%
Debt instrument lowest trading price	30%
Convertible Debt Four [Member]
Short-Term Debt [Line Items]
Debt instrument lowest trading price	70%

Schedule of Other Debt (Details

Schedule of Other Debt (Details) - USD ($)		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2020
Short-Term Debt [Line Items]
Totals, Principal		$ 1,426,026		$ 1,788,969
Long Term, Principal		161,864		150,000
Short Term, Principal		$ 1,264,162		$ 1,638,969
Non Convertible Loans [Member]
Short-Term Debt [Line Items]
Interest Rate			[1]		[2]
Totals, Principal		$ 170,000		$ 878,809
Merchant Debt [Member]
Short-Term Debt [Line Items]
Interest Rate		10%
Totals, Principal	[3]	$ 1,094,162		$ 760,160
SBA [Member]
Short-Term Debt [Line Items]
Interest Rate	[4]	3.75%		3.75%
Totals, Principal	[4]	$ 161,864		$ 150,000
Payroll Protection Program [Member]
Short-Term Debt [Line Items]
Debt interest rate						1%
[1]Interest rate of 10 maturity date is December 31, 2019 651,500 170,000 4.1 100.9 maturity dates ranged from July, 2023 to October, 2024. maturity dates ranged from April 4, 2023 to June 6, 2023. 150,000 3.75% 731 367,039 1 367,039

Schedule of Other Debt (Detai_2

Schedule of Other Debt (Details) (Parenthetical) - USD ($)		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt Instrument, Maturity Date		May 02, 2023
Note payable				$ 150,000
Accrued interest rate percent				3.75%
Debt Instrument periodic payment				$ 731
Debt instrument, maturity date description		March, 2020 to December, 2024
Non convertible debt		$ 1,426,026		$ 1,788,969
Merchant Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date description		maturity dates ranged from July, 2023 to October, 2024.		maturity dates ranged from April 4, 2023 to June 6, 2023.
Payroll Protection Program [Member]
Debt Instrument [Line Items]
Borrowed amount							$ 367,039
Paycheck Protection Programme [Member]
Debt Instrument [Line Items]
Borrowed amount						$ 367,039
Merchant Debt [Member]
Debt Instrument [Line Items]
Interest rate		10%
Debt instrument, maturity date description		maturity date is December 31, 2019
Convertible debt		$ 651,500
Non convertible debt	[1]	$ 1,094,162		$ 760,160
Non Convertible Loans [Member]
Debt Instrument [Line Items]
Interest rate			[2]		[3]
Non convertible debt		$ 170,000		$ 878,809
Minimum [Member]
Debt Instrument [Line Items]
Interest rate		1%
Minimum [Member] | Merchant Agreement [Member]
Debt Instrument [Line Items]
Interest rate		4.10%
Maximum [Member]
Debt Instrument [Line Items]
Interest rate		10%
Maximum [Member] | Merchant Agreement [Member]
Debt Instrument [Line Items]
Interest rate		100.90%
[1]During the years ended December 31, 2023 and 2022 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 4.1 100.9 maturity dates ranged from July, 2023 to October, 2024. maturity dates ranged from April 4, 2023 to June 6, 2023. 10 maturity date is December 31, 2019 651,500 170,000

Schedule of Related Party Debt

Schedule of Related Party Debt (Details) - USD ($)		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Totals, Principle			$ 731
Officers & Directors [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest Rate	[1]
Totals, Principle		$ 522,450	$ 521,950
Other Related Parties [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest Rate		12%	12%
Totals, Principle		$ 126,050	$ 120,850
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Totals, Principle		648,500	642,800
Discount, Principal			7,915
Net, Principal		$ 648,500	$ 634,885
[1]Interest varies from 12 120

Schedule of Related Party Deb_2

Schedule of Related Party Debt (Details) (Parenthetical)	Dec. 31, 2023
Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	1%
Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	10%
Related Party [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	12%
Related Party [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	120%

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Proceeds from convertible debt	$ 5,456,960	$ 4,907,222
Debt conversion per share	$ 2.50
Deferred cost current and non-current	$ 1,051,000	541,313
Repayment of convertible debt	2,742,409
Repayment of convertible debt	$ 2,742,409	$ 1,522,494
Debt instrument maturity date description	March, 2020 to December, 2024
Principal amount	$ 13,000,000
Debt face amount	$ 5,625,648
Number of shares issued	203,613	181,918
Debt Instrument, Repaid, Principal	$ 302,484
Losses on extinguishment of debt	(3,970,983)	$ (751,335)
Unamortized discount	645,471	455,517
Lenders [Member] | Standstill And Forbearance Agreements [Member]
Short-Term Debt [Line Items]
Principal amount	272,500
Two Lenders [Member] | Forbearance Agreements [Member]
Short-Term Debt [Line Items]
Repayment of convertible debt	272,500
Interest Payable	$ 253,425
Three Lenders [Member] | Forbearance Agreements [Member]
Short-Term Debt [Line Items]
Repayment of convertible debt		166,703
Interest Payable		$ 800,000
Common Stock [Member]
Short-Term Debt [Line Items]
Number of shares issued	203,613	181,918
Minimum [Member]
Short-Term Debt [Line Items]
Interest rate	1%
Minimum [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Debt instrument term		3 years
Maximum [Member]
Short-Term Debt [Line Items]
Interest rate	10%
Maximum [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Debt instrument term		5 years
Convertible Debt [Member]
Short-Term Debt [Line Items]
Proceeds from convertible debt	$ 5,500,000	$ 4,900,000
Amortization of debt discount	352,188
Principal amount	$ 6,325,263
Convertible Debt [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Convertible debt fair value disclosures		93,576
Convertible Debt [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Number of shares issued	2,552,300
Convertible Debt [Member] | Preferred Stock [Member]
Short-Term Debt [Line Items]
Number of shares issued	802
Convertible Debt [Member] | Convertible Common Stock [Member]
Short-Term Debt [Line Items]
Debt conversion per share	$ 2.50
Convertible debt fair value disclosures	$ 790,975	873,854
Convertible Debt [Member] | Convertible Preferred Stock [Member]
Short-Term Debt [Line Items]
Convertible debt fair value disclosures	$ 563,441
Convertible Debt [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument term	1 month
Interest rate	0%
Convertible Debt [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument term	12 months
Interest rate	18%
Convertible Notes [Member]
Short-Term Debt [Line Items]
Amortization of debt discount	$ 2,507,055	$ 1,694,028
New Loan [Member]
Short-Term Debt [Line Items]
Interest rate	10%	10%
Losses on extinguishment of debt	$ 3,970,983	$ 751,335
Short-term Non-Convertible Loan [Member]
Short-Term Debt [Line Items]
Debt conversion per share		$ 2.50
Amortization of debt discount	8,300	$ 83,835
Proceeds from Short-Term Debt	190,000	958,100
Original issue discount	8,300	91,750
Proceeds from (Repayments of) Related Party Debt	168,085	315,300
Unamortized discount	$ 0	$ 7,915
Short-term Non-Convertible Loan [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Interest rate	12%	12%
Short-term Non-Convertible Loan [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Interest rate	120%	120%

Summary of Preferred Stock (Det

Summary of Preferred Stock (Details) - USD ($)		Dec. 31, 2023	May 01, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Total Convertible Preferred Shares		$ 102		$ 1,098
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares				$ 3
Preferred Stock, Shares Authorized		850		850
Preferred stock, shares issued		75		300
Preferred stock, shares outstanding		75		300
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares				$ 806
Preferred Stock, Shares Authorized		240,000		240,000
Preferred stock, shares issued		0		80,570
Preferred stock, shares outstanding		0		80,570
Series H Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares				$ 100
Preferred Stock, Shares Authorized				10,000
Preferred stock, shares issued		0		10,000
Preferred stock, shares outstanding		0		10,000
Series J Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares				$ 35
Preferred Stock, Shares Authorized		6,250		6,250
Preferred stock, shares issued		0		3,458
Preferred stock, shares outstanding		0		3,458
Series K Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares				$ 68
Preferred Stock, Shares Authorized		15,000		15,000
Preferred stock, shares issued		0		6,880
Preferred stock, shares outstanding		0		6,880
Series AA Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares		$ 86		$ 86
Preferred Stock, Shares Authorized		10,000		10,000
Preferred stock, shares issued		8,645		8,645
Preferred stock, shares outstanding		8,645		8,645
Series BB Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	[1]	$ 12
Preferred Stock, Shares Authorized		1,000	1,000	1,000
Preferred stock, shares issued		1,219		0
Preferred stock, shares outstanding		1,219		0
Series CC Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares		$ 4
Preferred Stock, Shares Authorized		2,000	2,000	2,000
Preferred stock, shares issued		401		0
Preferred stock, shares outstanding		401		0
Series H 2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred Stock, Shares Authorized		21		21
Preferred stock, shares issued		0		21
Preferred stock, shares outstanding		0		21
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred Stock, Shares Authorized		20,000		20,000
Preferred stock, shares outstanding		0		0
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred Stock, Shares Authorized		313,960		313,960
Preferred stock, shares outstanding		0		0
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred Stock, Shares Authorized		279,256		279,256
Preferred stock, shares outstanding		0		0
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred Stock, Shares Authorized		88,098		88,098
Preferred stock, shares outstanding		0		0
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred Stock, Shares Authorized		500		500
Preferred stock, shares outstanding		0		0
[1] 219 1,000,000

Summary of Preferred Stock (D_2

Summary of Preferred Stock (Details) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	May 01, 2023	Nov. 11, 2011
Class of Stock [Line Items]
Stock issued during period, new shares	60,000	10,000
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01		$ 0.01
Preferred stock, shares authorized	850	850
Preferred stock, shares issued	75	300
Preferred stock, shares outstanding	75	300
Preferred stock, liquidation value	$ 300,000	$ 300,000
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	240,000	240,000
Preferred stock, shares issued	0	80,570
Preferred stock, shares outstanding	0	80,570
Series H Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized		10,000
Preferred stock, shares issued	0	10,000
Preferred stock, shares outstanding	0	10,000
Series J Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	6,250	6,250
Preferred stock, shares issued	0	3,458
Preferred stock, shares outstanding	0	3,458
Series K Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	15,000	15,000
Preferred stock, shares issued	0	6,880
Preferred stock, shares outstanding	0	6,880
Series AA Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	8,645	8,645
Preferred stock, shares outstanding	8,645	8,645
Stock issued during period, new shares	200
Series BB Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000	1,000	1,000
Preferred stock, shares issued	1,219	0
Preferred stock, shares outstanding	1,219	0
Stock issued during period, new shares	219
Short term liability	$ 1,000,000
Series CC Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,000	2,000	2,000
Preferred stock, shares issued	401	0
Preferred stock, shares outstanding	401	0
Series H 2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value		$ 0.01
Preferred stock, shares authorized	21	21
Preferred stock, shares issued	0	21
Preferred stock, shares outstanding	0	21
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares outstanding	0	0
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	313,960	313,960
Preferred stock, shares outstanding	0	0
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	279,256	279,256
Preferred stock, shares outstanding	0	0
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	88,098	88,098
Preferred stock, shares outstanding	0	0
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	500	500
Preferred stock, shares outstanding	0	0

Schedule of Options and Warrant

Schedule of Options and Warrants Outstanding and Exercisable (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Stock Options, Outstanding, Beginning Balance	1,307,822	1,333,101
Stock Options Weighted Average Price Per Share, Outstanding, Beginning Balance	$ 0.72	$ 0.72
Warrants, Outstanding, Beginning Balance	16,278,769	16,207,108
Warrants Weighted Average Price Per Share, Outstanding, Beginning Balance	$ 3.50	$ 3.50
Stock Options and Warrants, Outstanding, Beginning Balance	17,586,591	17,540,209
Stock Options and Warrants, Exercisable, Beginning Balance	17,570,591	17,308,567
Stock Options, Outstanding, Granted	7,151,238
Stock Options Weighted Average Price Per Share, Outstanding, Granted	$ 0.25
Warrants, Outstanding, Granted	100,000	277,500
Warrants Weighted Average Price Per Share, Outstanding, Granted	$ 3.50	$ 3.50
Stock Options and Warrants, Outstanding, Granted	7,251,238	277,500
Stock Options and Warrants, Exercisable, Granted
Stock Options, Outstanding, Exercised	(117,552)	(25,279)
Stock Options Weighted Average Price Per Share, Outstanding, Exercised	$ 0.69	$ 0.69
Warrants, Outstanding, Exercised
Warrants Weighted Average Price Per Share, Outstanding, Exercised
Stock Options and Warrants, Outstanding, Exercised	(117,552)	(25,279)
Stock Options, Outstanding, Expired
Stock Options Weighted Average Price Per Share, Outstanding, Expired
Warrants, Outstanding, Expired	(801,415)	(205,839)
Warrants Weighted Average Price Per Share, Outstanding, Expired	$ 3.50	$ 3.50
Stock Options and Warrants, Outstanding, Expired	(645,829)	(205,839)
Stock Options, Outstanding, Forfeited	(3,420,754)
Stock Options Weighted Average Price Per Share, Outstanding, Forfeited
Warrants, Outstanding, Forfeited
Warrants Weighted Average Price Per Share, Outstanding, Forfeited
Stock Options and Warrants, Outstanding, Forfeited	(3,420,754)
Stock Options, Outstanding, Ending Balance	4,920,754	1,307,822
Stock Options Weighted Average Price Per Share, Outstanding, Ending Balance	$ 0.25	$ 0.72
Warrants, Outstanding, Ending Balance	15,577,354	16,278,769
Warrants Weighted Average Price Per Share, Outstanding, Ending Balance	$ 3.50	$ 3.50
Stock Options and Warrants, Outstanding, Ending Balance	20,628,305	17,586,591
Stock Options and Warrants, Exercisable, Ending Balance	18,625,326	17,570,591

Schedule of Share-based Compens

Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	4,920,754
Options Outstanding, Remaining Contractual Life (In Years)	8 years 6 months
Options Outstanding, Weighted Average Exercise Price	$ 0.25
Options Exercisable, Number Exercisable | shares	3,047,972
Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term	7 years 9 months 18 days
Options Exercisable, Weighted Average Exercise Price	$ 0.25
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price lower range limit	0.25
Exercise price upper range limit	$ 1
Options Outstanding, Number Outstanding | shares	4,920,754
Options Outstanding, Remaining Contractual Life (In Years)	8 years 6 months
Options Outstanding, Weighted Average Exercise Price	$ 0.25
Options Exercisable, Number Exercisable | shares	3,047,972
Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term	7 years 9 months 18 days
Options Exercisable, Weighted Average Exercise Price	$ 0.25
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price lower range limit	1.01
Exercise price upper range limit	$ 3
Options Outstanding, Number Outstanding | shares
Options Outstanding, Weighted Average Exercise Price
Options Exercisable, Number Exercisable | shares
Options Exercisable, Weighted Average Exercise Price

Stockholders_ (Deficit) (Detail

Stockholders’ (Deficit) (Details Narrative)				5 Months Ended		9 Months Ended	12 Months Ended
	Apr. 13, 2023 USD ($) shares	Dec. 23, 2020	Nov. 11, 2011 USD ($) $ / shares shares	Jun. 06, 2024 shares	May 31, 2024 shares	Sep. 30, 2023	Dec. 31, 2023 USD ($) Integer $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Oct. 18, 2024 $ / shares	May 01, 2023 $ / shares shares	Dec. 30, 2021 shares
Class of Stock [Line Items]
Common stock, par value | $ / shares							$ 0.01	$ 0.01
Number of shares issued							60,000	10,000
Debt instrument, convertible price per shares | $ / shares							$ 2.50
Debt instrument, convertible, threshold trading days | Integer							5
Number of common stock for services rendered, shares								255,500
Number of common stock for services rendered, shares | $							$ 2,020,935	$ 392,175
Number of shares issued for conversion of debt							203,613	181,918
Value of shares issued for conversion of debt | $							$ 509,033	$ 467,092
Stock issued during period, shares, other							2,150,000
Stock Issued During Period, Value, Other | $							$ 2,082,544
Extension of warrants for Series AA preferred stock | $							$ 3,626,950
Options to shares outstanding							4,920,754	1,307,822	1,333,101
Unrecognized compensation cost | $							$ 373,532	$ 15,312
Number of share options exercised							117,552	25,279
Fair value of stock options | $							$ 81,111	$ 17,443
Number of shares issued for debt extensions							2,552,300	1,423,800
Value of stock issued for debt extensions | $							$ 2,028,748	$ 2,198,861
Value of stock issued for dividends paid in kind | $							$ 8,226,186	$ 2,943,139
Number of shares issued for debt							1,625,642	659,000
Conversion of stock, amount issued | $							$ 790,975	$ 873,854
Number of shares issued for conversion of preferred stock								4,400
Interest expense | $								$ 5,300,000	$ 2,700,000
Debt instrument description		we are obligated to issue 100,000 warrants if the loan is not repaid before January 23, 2021 and an additional 10,000 shares of common stock and 100,000 warrants if the loan is not repaid before February 23, 2021. We are also obligated to issue 10,000 shares of common stock and 200,000 warrants if the loan is not repaid before March 23, 2021. During the year ended December 31, 2021 the Company issued 400,000 warrants to this lender ($3.50 exercise price and five-year term) with a fair value of $600,298. The Company is also obligated to issue 10,000 shares of common stock to this lender every 31 days up to the loan’s maturity date on June 23, 2021
Professional Services [Member]
Class of Stock [Line Items]
Number of common stock for services rendered, shares							57,500
Number of common stock for services rendered, shares | $							$ 54,495
Minimum [Member]
Class of Stock [Line Items]
Debt instrument, interest rate, stated percentage							1%
Maximum [Member]
Class of Stock [Line Items]
Debt instrument, interest rate, stated percentage							10%
Lender [Member]
Class of Stock [Line Items]
Fair value of warrants | $									$ 600,298
Warrant, shares									400,000
Price per shares | $ / shares									$ 3.50
Unvested Stock-Based Awards [Member]
Class of Stock [Line Items]
Share price | $ / shares								$ 1.30
Unrecognized compensation cost | $								$ 15,312
Weighted average period								1 year 1 month 2 days
Options outstanding and exercisable intrinsic value | $								$ 0
Subsequent Event [Member]
Class of Stock [Line Items]
Number of common stock for services rendered, shares				1,274,000
Number of shares issued for conversion of debt				1,053,250
Share-Based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance												3,000,000
Other Plans [Member]
Class of Stock [Line Items]
Options to shares outstanding							4,920,754
Qualified And Non Qualified Stock Option [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Share price | $ / shares										$ 0.25
Investor Warrants [Member]
Class of Stock [Line Items]
Warrant to purchase shares of common stock									406,000
Fair value of warrants | $									$ 509,130
Preferred Stock [Member]
Class of Stock [Line Items]
Number of common stock for services rendered, shares | $
Value of shares issued for conversion of debt | $
Number of shares converted in to preferred stock							62
Fair value of stock options | $
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued							2,552,300	1,423,800
Number of common stock for services rendered, shares							2,150,000	255,500
Number of common stock for services rendered, shares | $							$ 21,500	$ 2,555
Number of shares issued for conversion of debt							203,613	181,918
Value of shares issued for conversion of debt | $							$ 2,036	$ 1,819
Number of shares converted in to preferred stock							245
Number of share options exercised							117,552	25,279
Fair value of stock options | $							$ 1,176	$ 253
Sale of common stock with fair value | $							$ 150,000	$ 25,000
Warrant [Member]
Class of Stock [Line Items]
Strike price, per share | $ / shares								$ 3.50
Number of shares issued							100,000	277,500
Fair value of warrants | $							$ 61,609	$ 280,608
Number of common stock for services rendered, shares | $
Value of shares issued for conversion of debt | $
Warrant, shares	8,897,603
Extension of warrants for Series AA preferred stock | $	$ 3,626,950
Weighted average remaining contractual term								1 year 6 months 10 days
Fair value of stock options | $
Warrant [Member] | New Conversion Debt [Member]
Class of Stock [Line Items]
Convertible shares issued							120,000
Convertible debt fair value | $							$ 93,576
Warrant issued for debt extension							100,000
Warrant issued for debt extension, value | $							$ 132,537
Warrant [Member] | Minimum [Member]
Class of Stock [Line Items]
Debt term								3 years
Warrant [Member] | Maximum [Member]
Class of Stock [Line Items]
Debt term								5 years
Common stock issuances [Member]
Class of Stock [Line Items]
Shares, Issued									10,000
Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized							1,000,000
Convertible preferred stock, par value | $ / shares							$ 0.01
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized							850	850
Convertible preferred stock, par value | $ / shares			$ 0.01				$ 0.01	$ 0.01
Sale of stock			843
Preferred stock redemption amount | $			$ 1,000
Proceeds from issuance of private placement | $			$ 843,000
Number of shares converted			84				84
Warrants term			5 years
Warrant to purchase shares of common stock			21
Strike price, per share | $ / shares			$ 24.30
Purchase price per units sold | $ / shares			$ 1,000
Stock conversion price per share | $ / shares							$ 19.50
Convertible preferred stock, conversion percentage							300%
Average daily trading volume | $							$ 50,000
Pro rate basis description							the holders of Series D Convertible Preferred Stock will have the right to participate on a pro-rata basis in up to 50% of such Subsequent Financing
Series D Convertible Preferred Stock [Member] | Business Combination [Member]
Class of Stock [Line Items]
Ownership percentage							50%
Series AA Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized							10,000	10,000
Convertible preferred stock, par value | $ / shares							$ 0.01	$ 0.01
Number of shares converted								4,400
Warrants term									5 years
Warrant to purchase shares of common stock									200,100
Strike price, per share | $ / shares									$ 3.50
Number of shares issued upon conversion, value | $									$ 509,130
Number of shares issued							200
Fair value of warrants | $									245,635
Losses on extinguishment | $									23,004
Accrued dividend | $								$ 1,727,275	$ 1,658,175
Number of shares issued for interest paid in kind							11,878,135	1,766,266
Number of shares issued for dividends paid in kind							729,571	236,221
Value of stock issued for dividends paid in kind | $							$ 386,936	$ 386,300
Series AA Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Accredited Investors [Member]
Class of Stock [Line Items]
Sale of stock									406
Warrant to purchase shares of common stock									406,000
Strike price, per share | $ / shares									$ 3.50
Number of preferred stock issued upon conversion									1,000
Common stock, par value | $ / shares									$ 0.01
Sale of stock, amount | $									$ 1,015,000
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Adjusted beneficial conversion feature value for deemed dividend | $							$ 0	$ 873,798
Series BB Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized							1,000	1,000			1,000
Convertible preferred stock, par value | $ / shares							$ 0.01	$ 0.01			$ 0.01
Number of shares issued							219
Preferred stock, conversion description							the Company converted 245 shares of Series BB convertible preferred stock and had 1,219 shares of Series BB convertible preferred stock outstanding which is 219 shares above the authorized of 1,000. As a result, 219 Series BB shares with an approximately fair value of $1,000,000 is included as preferred stock liability as of December 31, 2023.
Preferred stock liability | $							$ 1,000,000
Number of shares issued for conversion of debt							624,000
Number of shares converted in to preferred stock							62
Series BB Convertible Preferred Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Number of shares converted				7,224,000
Number of preferred stock issued upon conversion				722
Number of common stock for services rendered, shares				123
Number of shares issued for conversion of debt				323
Stock issued during period, shares, other				745
Series BB Convertible Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued for conversion of debt							2,454,000
Series CC Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized							2,000	2,000			2,000
Convertible preferred stock, par value | $ / shares							$ 0.01	$ 0.01			$ 0.01
Series BB Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, par value | $ / shares							$ 0.01
Number of shares converted							10,000
Preferred stock voting rights							The holders of Series BB Preferred Stock shall have the right to vote along with the holders of Common Stock in an amount equal to 10,000 votes for each share of Series BB Preferred Stock held.
Debt instrument, interest rate, stated percentage							300%
Debt instrument, convertible price per shares | $ / shares							$ 2.50
Number of common stock for services rendered, shares							233
Number of common stock for services rendered, shares | $							$ 1,360,867
Number of shares issued for conversion of debt							822
Value of shares issued for conversion of debt | $							$ 3,071,914
Debt conversion extension amount | $							$ 397,384
Number of shares issued for interest paid in kind							220
Stock issued during period, shares, interest paid in preferred stock liability							602,616
Series BB Preferred Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Number of shares issued					880
Series BB Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares converted in to preferred stock							128
Stock issued during period, value, conversion of units | $							$ 563,441
Series CC Preferred Stock [Member]
Class of Stock [Line Items]
Debt instrument, interest rate, stated percentage							8%
Preferred stock remain outstanding percentage						10%
Preferred stock, dividend rate, percentage							75%
Outstanding shares, precentage							50%
Preferred stock liquidation Preference value | $ / shares							$ 25,000
Preferred stock, convertible, conversion price | $ / shares							$ 2.50
Debt instrument, convertible, threshold percentage of stock price trigger							300%
Debt instrument, convertible, threshold trading days | Integer							10
Debt instrument convertible benefically percentage							4.99%
Stock issued during period, shares, other							401
Stock Issued During Period, Value, Other | $							$ 10,017,208
Series DK Convertible Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued for conversion of debt							537,940

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)			5 Months Ended		9 Months Ended	12 Months Ended
	May 01, 2024 USD ($)	Jan. 09, 2024 USD ($) $ / shares shares	Jun. 06, 2024 $ / shares shares	May 31, 2024 USD ($) Integer shares	Mar. 24, 2025 USD ($) Integer	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 $ / shares
Subsequent Event [Line Items]
Conversion of debt and interest for common stock, shares						203,613	181,918
Value of shares issued | $						$ 2,028,748	$ 2,198,861
Stock issued for extensions and default						2,150,000
Exercise price | $ / shares						$ 0.25	$ 0.72	$ 0.72
Debt Instrument, Face Amount | $						$ 13,000,000
Common stock issued for debt extension, shares						60,000	10,000
Stock issued for services							255,500
Stock option, grants						7,151,238
Exercise price, grants | $ / shares						$ 0.25
Maximum [Member]
Subsequent Event [Line Items]
Interest rate						10%
Minimum [Member]
Subsequent Event [Line Items]
Interest rate						1%
Common Stock [Member]
Subsequent Event [Line Items]
Conversion of debt and interest for common stock, shares						203,613	181,918
Value of shares issued | $						$ 25,523	$ 14,238
Common stock issued for debt extension, shares						2,552,300	1,423,800
Stock issued for services						2,150,000	255,500
Series BB Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of debt and interest for common stock, shares						822
Interest rate						300%
Conversion of stock into common stock						10,000
Stock issued for services						233
Series BB Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of debt and interest for common stock, shares						624,000
Common stock issued for debt extension, shares						219
Series BB Convertible Preferred Stock [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Conversion of debt and interest for common stock, shares						2,454,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Conversion of debt and interest for common stock, shares			1,053,250
Debt Instrument, Convertible, Number of Equity Instruments | Integer					22
Repayments of Debt | $				$ 272,852	$ 7,281,000
Stock issued for services			1,274,000
Stock option, grants			803,750
Exercise price, grants | $ / shares			$ 0.30
Stock option, grants contractual term			10 years
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Payments for rent | $	$ 13,678
Subsequent Event [Member] | Minimum [Member]
Subsequent Event [Line Items]
Payments for rent | $	$ 11,651
Subsequent Event [Member] | Common Stock [Member] | Three Lender [Member]
Subsequent Event [Line Items]
Common stock issued for debt extension, shares				353,000
Subsequent Event [Member] | Series BB Preferred Stock [Member]
Subsequent Event [Line Items]
Common stock issued for debt extension, shares				880
Subsequent Event [Member] | Series BB Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of debt and interest for common stock, shares			323
Stock issued for extensions and default			745
Convertible preferred stock, converted.			722
Conversion of stock into common stock			7,224,000
Stock issued for services			123
Stock issued over the authorized amount			1,091
Subsequent Event [Member] | Asset Purchase Agreement [Member] | CBH International LLC [Member] | Uncle Buds [Member]
Subsequent Event [Line Items]
Long-term loan | $		$ 734,000
Exercise price | $ / shares		$ 0.30
Vesting percentage		100%
Option term		10 years
Debt Instrument, Convertible, Number of Equity Instruments | Integer				13
Debt Instrument, Face Amount | $				$ 3,100,000
Subsequent Event [Member] | Asset Purchase Agreement [Member] | CBH International LLC [Member] | Uncle Buds [Member] | Qualified And Non Qualified Stock Option [Member]
Subsequent Event [Line Items]
Stock issued for extensions and default		8,000,000
Subsequent Event [Member] | Asset Purchase Agreement [Member] | CBH International LLC [Member] | Uncle Buds [Member] | Maximum [Member]
Subsequent Event [Line Items]
Interest rate				72%
Debt Instrument, Term				12 years
Subsequent Event [Member] | Asset Purchase Agreement [Member] | CBH International LLC [Member] | Uncle Buds [Member] | Minimum [Member]
Subsequent Event [Line Items]
Interest rate				0%
Debt Instrument, Term				1 year
Subsequent Event [Member] | Asset Purchase Agreement [Member] | CBH International LLC [Member] | Uncle Buds [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Conversion of debt and interest for common stock, shares		2,540,000
Subsequent Event [Member] | Asset Purchase Agreement [Member] | CBH International LLC [Member] | Uncle Buds [Member] | Common Stock [Member] | Maximum [Member]
Subsequent Event [Line Items]
Value of shares issued | $		$ 4,000,000
Subsequent Event [Member] | Asset Purchase Agreement [Member] | CBH International LLC [Member] | Uncle Buds [Member] | Convertible Series D D Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of debt and interest for common stock, shares		127